aldosterone has been researched along with Left Ventricular Hypertrophy in 160 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The mineralocorticoid receptor antagonist spironolactone has been shown to improve cardiac function and reverse left ventricular hypertrophy in heart failure patients, but there are no consistent findings on the efficacy and safety in hemodialysis patients." | 9.41 | Research Progress on the Efficacy and Safety of Spironolactone in Reversing Left Ventricular Hypertrophy in Hemodialysis Patients. ( Chen, Z; Li, Z; Liu, R; Lu, G; Sun, Y; Sun, Z, 2023) |
| "Angiotensin II receptor blockers (ARBs) have been widely used to treat hypertension and large-scale clinical studies have shown various benefits." | 9.22 | Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study). ( Arimoto, M; Hata, H; Osaka, S; Sakino, H; Sezai, A; Shiono, M; Yaoita, H, 2016) |
| " In nondialytic chronic kidney disease, spironolactone was safe and effective in reducing left ventricular hypertrophy." | 9.20 | Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients. ( Barretti, P; Caramori, JC; Castro, AD; De Stefano, LM; Feniman-De-Stefano, GM; Franco, RJ; Martin, LC; Xavier, PS; Zanati-Basan, SG, 2015) |
| "5 mg hydrochorothiazide + 5 mg amlodipine, 86 patients with resistant hypertension were randomized to the add-on 25 mg spironolactone (MRB group, n = 46) or 5 mg ramipril (RASB group, n = 40) groups for 12 weeks." | 9.19 | Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension. ( Azizi, M; Bobrie, G; Chatellier, G; Frank, M; Ménard, J; Perdrix, L; Plouin, PF, 2014) |
| "The Aliskiren in Left Ventricular Hypertrophy (ALLAY) trial randomised 465 hypertensive overweight subjects with LVH to the direct renin inhibitor aliskiren 300 mg, losartan 100 mg or the combination and followed patients for 9 months." | 9.15 | Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension. ( Appelbaum, E; Dahlöf, B; Desai, A; Lukashevich, V; Pouleur, AC; Prescott, MF; Smith, BA; Solomon, SD; Uno, H, 2011) |
| "Participants enrolled in this trial were outpatients with essential hypertension after cardiac surgery who had received candesartan for more than one year." | 9.15 | Effects of olmesartan on the renin-angiotensin-aldosterone system for patients with essential hypertension after cardiac surgery--investigation using a candesartan change-over study. ( Hata, M; Sezai, A; Shiono, M; Soma, M; Unosawa, S; Wakui, S; Yoshitake, I, 2011) |
| " Spironolactone is thought to be an important addition to resistant hypertension (RH) treatment." | 9.14 | Aldosterone excess or escape: Treating resistant hypertension. ( Adriana de Souza, L; Coca, A; Coelho, OR; Ferreira-Melo, S; Martins, LC; Moreno, H; Pimenta, E; Sierra, C; Ubaid-Girioli, S; Yugar-Toledo, JC, 2009) |
| "A total of 50 stable outpatients with essential hypertension who had received candesartan for more than 1 year were randomized into two groups: control group (n=25): continuous candesartan treatment at a stable dose; and olmesartan group (n=25): candesartan (8 mg day(-1)) was changed to olmesartan given at a dose of 20 mg day(-1)." | 9.14 | Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension. ( Fujii, M; Horie, M; Kawahara, C; Nishiyama, K; Tsutamoto, T; Yamaji, M; Yamamoto, T, 2010) |
| "The patients with essential hypertension were randomly divided into 2 groups; 1 group was treated with an ARB, candesartan (8 mg/day), for 1 year (ARB group) and other group was treated with the ARB for the first 6 months and with the ARB plus SPRL (25 mg/day) for the next 6 months (combination group)." | 9.12 | Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. ( Date, T; Kawai, M; Mochizuki, S; Seki, S; Shimizu, M; Taniguchi, I; Taniguchi, M; Yoshida, S, 2006) |
| "Patients with mild-to-moderate primary hypertension and left ventricular hypertrophy were randomized in a double-blind study to receive treatment with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan (n = 43), or the beta1-adrenergic receptor blocker atenolol (n = 43)." | 9.10 | Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. ( Hägg, A; Kahan, T; Karlsson, J; Kurland, L; Lind, L; Malmqvist, K; Melhus, H; Nyström, F; Ohman, P, 2002) |
| " In the present study, we examined the effect on left ventricular hypertrophy of adding a low dose of the mineralocorticoid receptor antagonist spironolactone (25 mg/d) to an angiotensin-converting enzyme inhibitor (enalapril maleate) in patients with essential hypertension." | 9.09 | Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. ( Saruta, T; Sato, A; Suzuki, Y, 1999) |
| " This study suggests that telmisartan (TEL) can inhibit myocardial fibrosis of hypertensive left ventricular hypertrophy (LVH) through the transforming growth factor-β1 (TGF-β1)/Smad signaling pathway." | 7.80 | Telmisartan delays myocardial fibrosis in rats with hypertensive left ventricular hypertrophy by TGF-β1/Smad signal pathway. ( Guan, G; Ma, A; Shao, L; Tian, G; Wang, J; Wang, Y; Zhang, Y, 2014) |
| "In 205 patients with untreated essential hypertension, we measured components of the renin-angiotensin-aldosterone system, plasma levels of fibrinogen, D-dimer, prothrombin fragment 1 + 2 (F1 + 2), and plasminogen activator inhibitor-1 (PAI-1), and assessed cardiac characteristics with standard echocardiography." | 7.79 | Association of aldosterone with left ventricular mass in hypertension: interaction with plasma fibrinogen levels. ( Catena, C; Colussi, G; Sechi, LA; Valeri, M, 2013) |
| " In the present study, the effect of a subdose of fasudil, a selective ROCK inhibitor, on systemic hypertension and myocardium fibrosis induced by aldosterone was investigated in uninephrectomized Sprague-Dawley rats (SD)." | 7.77 | Subdose of fasudil suppresses myocardial fibrosis in aldosterone-salt-treated uninephrectomized rats. ( Guo, P; Masaki, T; Mori, H; Nishiyama, A; Wu, C, 2011) |
| " Blood pressure, heart rate, concentrations of aldosterone, urea, creatinine, electrolytes, and protein, index of hypertrophy of visceral organs, and 24-h diuresis were evaluated." | 7.74 | Effect of spironolactone on hypertrophy of left ventricular myocardium in wistar rats with experimental uremia. ( Beresneva, ON; Esaian, AM; Karabayeva, AZh; Kayukov, IG; Kotenko, LV; Parastaeva, MM; Sevastyanova, IE, 2008) |
| "We investigated the pathophysiological role of the cardiac adrenomedullin (AM) system, including the ligand, receptor and amidating activity in the hypertrophied heart in severe hypertension." | 7.72 | Upregulation of ligand, receptor system, and amidating activity of adrenomedullin in left ventricular hypertrophy of severely hypertensive rats: effects of angiotensin-converting enzyme inhibitors and diuretic. ( Akimoto, K; Minamino, N; Mori, Y; Nishikimi, T; Tadokoro, K; Wang, X, 2003) |
| "Clinical evaluation of hypotensive effectiveness and the cardiovascular and side effects of enalapril monotherapy of significant essential hypertension (SEH) in adolescents was performed." | 7.69 | [Evaluation of the efficacy and safety of monotherapy for significant essential hypertension in adolescents with use of enalapril]. ( Cichocka, E; Januszewicz, P; Kawalec, W; Wyszyńska, T, 1995) |
| "Primary aldosteronism (PA) is associated with inappropriate left ventricular hypertrophy (LVH) in relation to a given gender and body size." | 6.78 | Twenty-four-hour urinary aldosterone predicts inappropriate left ventricular mass index in patients with primary aldosteronism. ( Chang, YY; Changh, YS; Chen, MF; Chueh, SC; Ho, YL; Hu, YH; Hung, CS; Lee, JK; Lin, YH; Sui, MJ; Wu, KD; Wu, VC; Wu, XM; Yang, SY, 2013) |
| "Non-culprit intermediate coronary atherosclerosis was assessed on intravascular ultrasound." | 6.77 | Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor. ( Ebina, T; Hibi, K; Kimura, K; Kosuge, M; Kusama, I; Morita, S; Nozawa, N; Okuda, J; Ozaki, H; Tsukahara, K; Umemura, S; Yano, H, 2012) |
| "The neurohormonal model of congestive heart failure (CHF) has replaced the previously accepted hemodynamic model." | 6.43 | The role of aldosterone blockers in the management of chronic heart failure. ( Coca, SG; Perazella, MA, 2005) |
| "Aldosterone has hypertrophic and profibrotic effects on the heart." | 5.91 | Serum aldosterone effect on left ventricular structure and diastolic function in essential hypertension. ( Al-Hashedi, EM; Juvenal, H; Mohammed, AA; Yu, J; Zhao, X, 2023) |
| "In patients with KCNJ5-mutated APA, left ventricular hypertrophy was significantly decreased by surgical treatment in patients from either Cured or Improved groups, although those patients with wild-type KCNJ5 showed no change." | 5.48 | KCNJ5 mutation as a predictor for resolution of hypertension after surgical treatment of aldosterone-producing adenoma. ( Kitamoto, T; Nishikawa, T; Omura, M; Saito, J; Suematsu, S, 2018) |
| "Aldosterone has hypertrophic and profibrotic effects on the heart." | 5.42 | Plasma aldosterone and left ventricular diastolic function in treatment-naïve patients with hypertension: tissue-Doppler imaging study. ( Catena, C; Kraigher-Krainer, E; Pieske, B; Pilz, S; Sechi, LA; Tomaschitz, A; Verheyen, N, 2015) |
| "The mineralocorticoid receptor antagonist spironolactone has been shown to improve cardiac function and reverse left ventricular hypertrophy in heart failure patients, but there are no consistent findings on the efficacy and safety in hemodialysis patients." | 5.41 | Research Progress on the Efficacy and Safety of Spironolactone in Reversing Left Ventricular Hypertrophy in Hemodialysis Patients. ( Chen, Z; Li, Z; Liu, R; Lu, G; Sun, Y; Sun, Z, 2023) |
| "Treatment with aldosterone did not alter mitochondrial respiratory function but accelerated Ca(2+)-induced MPT in SSM, but not IFM, compared with healthy old and young beagles." | 5.39 | Enhanced resistance to permeability transition in interfibrillar cardiac mitochondria in dogs: effects of aging and long-term aldosterone infusion. ( Asemu, G; Cox, JW; Dabkowski, ER; Hecker, PA; Hoppel, CL; O'Connell, KA; Rastogi, S; Ribeiro, RF; Sabbah, HN; Shekar, KC; Stanley, WC; Xu, W, 2013) |
| "Aldosterone and LVH were investigated in 240 and 110 subjects respectively." | 5.36 | Association of HSD3B1 and HSD3B2 gene polymorphisms with essential hypertension, aldosterone level, and left ventricular structure. ( Aoi, N; Izumi, Y; Matsumoto, K; Nakayama, T; Sato, M; Sato, N; Shimodaira, M; Soma, M, 2010) |
| "The aldosterone level was comparable in both groups." | 5.35 | Diastolic dysfunction is associated with insulin resistance, but not with aldosterone level in normotensive offspring of hypertensive families. ( Poredos, P; Trojar, A; Zeljko, T; Zizek, B, 2008) |
| "A total of 25 patients with primary aldosteronism caused by Conn's adenoma, 29 patients with renovascular hypertension, and 29 patients with essential hypertension (EHT) were included in the present study." | 5.33 | Role of aldosterone in left ventricular hypertrophy in hypertension. ( Fujii, K; Iida, M; Matsumura, K; Oka, M; Oniki, H, 2006) |
| "Primary hyperaldosteronism is a well-recognized cause of secondary hypertension." | 5.32 | Serum aldosterone and the incidence of hypertension in nonhypertensive persons. ( Benjamin, EJ; Evans, JC; Larson, MG; Levy, D; Meigs, JB; Rifai, N; Vasan, RS; Wilson, PW, 2004) |
| "Aldosterone-salt treatment induced, (1) arterial hypertension (+40%) and LV hypertrophy (+60%) without altering LV-fractional shortening, (2) an increase in plasma norepinephrine levels (+262%) and suppression of renin activity." | 5.30 | Modifications of myocardial Na+,K(+)-ATPase isoforms and Na+/Ca2+ exchanger in aldosterone/salt-induced hypertension in guinea pigs. ( Carayon, A; Charlemagne, D; Lechat, P; Mougenot, N; Ramírez-Gil, JF; Trouvé, P, 1998) |
| "Cardiac fibrosis is linked to aldosterone-induced hypertension, but the effects on in vivo left ventricular (LV) function are not established." | 5.30 | In vivo left ventricular function and collagen expression in aldosterone/salt-induced hypertension. ( Charlemagne, D; Delcayre, C; Lechat, P; Mougenot, N; Ramirez-Gil, JF; Robert, V; Trouve, P; Wassef, M, 1998) |
| "Angiotensin II receptor blockers (ARBs) have been widely used to treat hypertension and large-scale clinical studies have shown various benefits." | 5.22 | Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study). ( Arimoto, M; Hata, H; Osaka, S; Sakino, H; Sezai, A; Shiono, M; Yaoita, H, 2016) |
| " In nondialytic chronic kidney disease, spironolactone was safe and effective in reducing left ventricular hypertrophy." | 5.20 | Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients. ( Barretti, P; Caramori, JC; Castro, AD; De Stefano, LM; Feniman-De-Stefano, GM; Franco, RJ; Martin, LC; Xavier, PS; Zanati-Basan, SG, 2015) |
| "5 mg hydrochorothiazide + 5 mg amlodipine, 86 patients with resistant hypertension were randomized to the add-on 25 mg spironolactone (MRB group, n = 46) or 5 mg ramipril (RASB group, n = 40) groups for 12 weeks." | 5.19 | Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension. ( Azizi, M; Bobrie, G; Chatellier, G; Frank, M; Ménard, J; Perdrix, L; Plouin, PF, 2014) |
| "HYPOTHESIS/ INTRODUCTION: We investigated whether diabetes modified the effectiveness of renin-angiotensin-aldosterone system (RAAS) inhibition on left ventricular hypertrophy (LVH) regression in hypertensive patients in the Aliskiren in Left Ventricular Hypertrophy (ALLAY) trial." | 5.16 | Influence of diabetes on efficacy of aliskiren, losartan or both on left ventricular mass regression. ( Appelbaum, E; Dahlof, B; Pouleur, AC; Prescott, M; Smith, B; Solomon, SD; Takeuchi, M; Vardeny, O; Verma, A, 2012) |
| "The Aliskiren in Left Ventricular Hypertrophy (ALLAY) trial randomised 465 hypertensive overweight subjects with LVH to the direct renin inhibitor aliskiren 300 mg, losartan 100 mg or the combination and followed patients for 9 months." | 5.15 | Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension. ( Appelbaum, E; Dahlöf, B; Desai, A; Lukashevich, V; Pouleur, AC; Prescott, MF; Smith, BA; Solomon, SD; Uno, H, 2011) |
| "Participants enrolled in this trial were outpatients with essential hypertension after cardiac surgery who had received candesartan for more than one year." | 5.15 | Effects of olmesartan on the renin-angiotensin-aldosterone system for patients with essential hypertension after cardiac surgery--investigation using a candesartan change-over study. ( Hata, M; Sezai, A; Shiono, M; Soma, M; Unosawa, S; Wakui, S; Yoshitake, I, 2011) |
| " Spironolactone is thought to be an important addition to resistant hypertension (RH) treatment." | 5.14 | Aldosterone excess or escape: Treating resistant hypertension. ( Adriana de Souza, L; Coca, A; Coelho, OR; Ferreira-Melo, S; Martins, LC; Moreno, H; Pimenta, E; Sierra, C; Ubaid-Girioli, S; Yugar-Toledo, JC, 2009) |
| "A total of 50 stable outpatients with essential hypertension who had received candesartan for more than 1 year were randomized into two groups: control group (n=25): continuous candesartan treatment at a stable dose; and olmesartan group (n=25): candesartan (8 mg day(-1)) was changed to olmesartan given at a dose of 20 mg day(-1)." | 5.14 | Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension. ( Fujii, M; Horie, M; Kawahara, C; Nishiyama, K; Tsutamoto, T; Yamaji, M; Yamamoto, T, 2010) |
| "The patients with essential hypertension were randomly divided into 2 groups; 1 group was treated with an ARB, candesartan (8 mg/day), for 1 year (ARB group) and other group was treated with the ARB for the first 6 months and with the ARB plus SPRL (25 mg/day) for the next 6 months (combination group)." | 5.12 | Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. ( Date, T; Kawai, M; Mochizuki, S; Seki, S; Shimizu, M; Taniguchi, I; Taniguchi, M; Yoshida, S, 2006) |
| "Patients with mild-to-moderate primary hypertension and left ventricular hypertrophy were randomized in a double-blind study to receive treatment with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan (n = 43), or the beta1-adrenergic receptor blocker atenolol (n = 43)." | 5.10 | Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. ( Hägg, A; Kahan, T; Karlsson, J; Kurland, L; Lind, L; Malmqvist, K; Melhus, H; Nyström, F; Ohman, P, 2002) |
| " In the present study, we examined the effect on left ventricular hypertrophy of adding a low dose of the mineralocorticoid receptor antagonist spironolactone (25 mg/d) to an angiotensin-converting enzyme inhibitor (enalapril maleate) in patients with essential hypertension." | 5.09 | Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. ( Saruta, T; Sato, A; Suzuki, Y, 1999) |
| "This study compared the effects of 1 year of monotherapy with a calcium-channel antagonist (nilvadipine; NIL), an angiotensin-converting enzyme (ACE) inhibitor (temocapril; TEM), or a new vasodilator (cadralazine; CAD) on left ventricular (LV) hypertrophy in essential hypertension." | 5.08 | The effects of long-term treatment on left ventricular hypertrophy in patients with essential hypertension: relation to changes in neurohumoral factors. ( Inoue, H; Oh-hashi, S; Takata, M; Tomita, S; Ueno, H; Yasumoto, K, 1997) |
| " Studies using gene-modified mice deficient in Nox2 activity indicate that Nox2 activation contributes to angiotensin II-induced cardiomyocyte hypertrophy, atrial fibrillation, and the development of interstitial fibrosis but may also positively modulate physiological excitation-contraction coupling." | 4.89 | NADPH oxidases in heart failure: poachers or gamekeepers? ( Ghigo, A; Hirsch, E; Perino, A; Shah, AM; Zhang, M, 2013) |
| " Spironolactone and eplerenone are the mineralocorticoid receptor (MR) antagonists currently available for the treatment of hypertension." | 4.82 | Mineralocorticoid receptor antagonists and hypertension: is there a rationale? ( Gumieniak, O; Williams, GH, 2004) |
| " Due to the potential importance of these mechanisms, the finding that there is a significant correlation between aldosterone production and mortality in patients with heart failure, as well as evidence that an aldosterone antagonist, spironolactone, when administered to patients with heart failure treated with conventional therapy including an ACE inhibitor results in increased diuresis and symptomatic improvement, an international prospective multicenter study has been organized, the Randomized Aldactone Evaluation Study (RALES Pilot Study), to evaluate the safety of blocking the effects of aldosterone in patients with heart failure treated with an ACE inhibitor." | 4.79 | "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. ( Pitt, B, 1995) |
| " This study suggests that telmisartan (TEL) can inhibit myocardial fibrosis of hypertensive left ventricular hypertrophy (LVH) through the transforming growth factor-β1 (TGF-β1)/Smad signaling pathway." | 3.80 | Telmisartan delays myocardial fibrosis in rats with hypertensive left ventricular hypertrophy by TGF-β1/Smad signal pathway. ( Guan, G; Ma, A; Shao, L; Tian, G; Wang, J; Wang, Y; Zhang, Y, 2014) |
| "In 205 patients with untreated essential hypertension, we measured components of the renin-angiotensin-aldosterone system, plasma levels of fibrinogen, D-dimer, prothrombin fragment 1 + 2 (F1 + 2), and plasminogen activator inhibitor-1 (PAI-1), and assessed cardiac characteristics with standard echocardiography." | 3.79 | Association of aldosterone with left ventricular mass in hypertension: interaction with plasma fibrinogen levels. ( Catena, C; Colussi, G; Sechi, LA; Valeri, M, 2013) |
| " In the present study, the effect of a subdose of fasudil, a selective ROCK inhibitor, on systemic hypertension and myocardium fibrosis induced by aldosterone was investigated in uninephrectomized Sprague-Dawley rats (SD)." | 3.77 | Subdose of fasudil suppresses myocardial fibrosis in aldosterone-salt-treated uninephrectomized rats. ( Guo, P; Masaki, T; Mori, H; Nishiyama, A; Wu, C, 2011) |
| "BC can inhibit left ventricular hypertrophy, plasma level of angiotensin II and aldosterone to some extent in SHR." | 3.76 | [Effects of Bai-Chuan capsule on left ventricular hypertrophy and correlative indexes]. ( Duan, HJ; He, LC; Zhan, YZ; Zhang, Y, 2010) |
| " Blood pressure, heart rate, concentrations of aldosterone, urea, creatinine, electrolytes, and protein, index of hypertrophy of visceral organs, and 24-h diuresis were evaluated." | 3.74 | Effect of spironolactone on hypertrophy of left ventricular myocardium in wistar rats with experimental uremia. ( Beresneva, ON; Esaian, AM; Karabayeva, AZh; Kayukov, IG; Kotenko, LV; Parastaeva, MM; Sevastyanova, IE, 2008) |
| "We investigated the pathophysiological role of the cardiac adrenomedullin (AM) system, including the ligand, receptor and amidating activity in the hypertrophied heart in severe hypertension." | 3.72 | Upregulation of ligand, receptor system, and amidating activity of adrenomedullin in left ventricular hypertrophy of severely hypertensive rats: effects of angiotensin-converting enzyme inhibitors and diuretic. ( Akimoto, K; Minamino, N; Mori, Y; Nishikimi, T; Tadokoro, K; Wang, X, 2003) |
| "In 43 untreated patients with hypertension with electrocardiographic left ventricular hypertrophy, we measured relative wall thickness and left ventricular mass index by echocardiography and by magnetic resonance imaging (n = 32), intima-media cross-sectional area, and distensibility of the common carotid arteries by ultrasound, media/lumen ratio of isolated subcutaneous resistance arteries by myography, and median 24-hour systolic BP (n = 40), serum insulin, and plasma levels of epinephrine, norepinephrine, renin, angiotensin II, aldosterone, and endothelin." | 3.71 | Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension. ( Devereux, RB; Dige-Petersen, H; Frandsen, E; Hermann, KL; Ibsen, H; Olsen, MH; Rokkedal, J; Wachtell, K, 2002) |
| "In a previous study we found that high angiotensin II levels in relation to the corresponding urinary sodium excretion aggravate left ventricular hypertrophy in hypertensive patients." | 3.70 | Inadequate suppression of angiotensin II modulates left ventricular structure in humans. ( Hilgers, K; Langenfeld, MR; Schlaich, MP; Schmieder, RE; Schobel, HP, 1998) |
| "We investigated the pathophysiological significance of adrenomedullin (AM) in the development of left ventricular hypertrophy (LVH)." | 3.70 | Ventricular adrenomedullin levels correlate with the extent of cardiac hypertrophy in rats. ( Dohi, K; Horio, T; Kangawa, K; Matsuo, H; Morimoto, A; Nagaya, N; Nishikimi, T; Yoshihara, F, 1999) |
| "Clinical evaluation of hypotensive effectiveness and the cardiovascular and side effects of enalapril monotherapy of significant essential hypertension (SEH) in adolescents was performed." | 3.69 | [Evaluation of the efficacy and safety of monotherapy for significant essential hypertension in adolescents with use of enalapril]. ( Cichocka, E; Januszewicz, P; Kawalec, W; Wyszyńska, T, 1995) |
| "Primary aldosteronism (PA) is associated with inappropriate left ventricular hypertrophy (LVH) in relation to a given gender and body size." | 2.78 | Twenty-four-hour urinary aldosterone predicts inappropriate left ventricular mass index in patients with primary aldosteronism. ( Chang, YY; Changh, YS; Chen, MF; Chueh, SC; Ho, YL; Hu, YH; Hung, CS; Lee, JK; Lin, YH; Sui, MJ; Wu, KD; Wu, VC; Wu, XM; Yang, SY, 2013) |
| "Non-culprit intermediate coronary atherosclerosis was assessed on intravascular ultrasound." | 2.77 | Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor. ( Ebina, T; Hibi, K; Kimura, K; Kosuge, M; Kusama, I; Morita, S; Nozawa, N; Okuda, J; Ozaki, H; Tsukahara, K; Umemura, S; Yano, H, 2012) |
| "Primary aldosteronism is the most frequent cause of secondary hypertension and is associated with more prominent left ventricular hypertrophy and increased myocardial fibrosis." | 2.77 | Adrenalectomy reverses myocardial fibrosis in patients with primary aldosteronism. ( Chang, HW; Chueh, SC; Ho, YL; Lee, HH; Lee, JK; Lin, CY; Lin, LC; Lin, YH; Liu, YC; Lo, MT; Wu, KD; Wu, VC; Wu, XM, 2012) |
| "Primary aldosteronism (PA) is a common cause of secondary hypertension and is associated with worse cardiovascular outcomes." | 2.72 | Left ventricular remodeling and dysfunction in primary aldosteronism. ( Chang, YY; Chen, ZW; Hung, CS; Lin, YH; Pan, CT; Tsai, CH; Wu, VC, 2021) |
| "Treatment with captopril affected only plasma renin activity (increase) and aldosterone (decrease)." | 2.69 | Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. ( Bichet, D; Ciampi, A; de Champlain, J; Harel, F; Moyé, LA; Pfeffer, M; Rouleau, JL; Vantrimpont, P, 1998) |
| "Primary aldosteronism (PA) is one of the common forms of curable hypertension." | 2.46 | Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. ( Catena, C; Colussi, G; Di Fabio, A; Sechi, LA, 2010) |
| "The neurohormonal model of congestive heart failure (CHF) has replaced the previously accepted hemodynamic model." | 2.43 | The role of aldosterone blockers in the management of chronic heart failure. ( Coca, SG; Perazella, MA, 2005) |
| "The role of left ventricular hypertrophy as an independent risk factor for subsequent cardio-vascular events is well established, therefore the authors, in this brief review, describe the endocrine function of the heart and the role played by various factors, including hormones, in the development of cardiac remodeling during the course of hypertension." | 2.40 | [Pathophysiology of left ventricular hypertrophy in arterial hypertension]. ( Braconi-Quintaje, S; Lang, U; Vallotton, MB, 1997) |
| "Left ventricular hypertrophy is considered to be an independent risk factor giving rise to ischemia, arrhythmias, and left ventricular dysfunction." | 2.39 | Substrate metabolism, hormone interaction, and angiotensin-converting enzyme inhibitors in left ventricular hypertrophy. ( Gohlke, P; Spitznagel, H; Unger, T; Zhu, YC; Zhu, YZ, 1996) |
| "Aldosterone has hypertrophic and profibrotic effects on the heart." | 1.91 | Serum aldosterone effect on left ventricular structure and diastolic function in essential hypertension. ( Al-Hashedi, EM; Juvenal, H; Mohammed, AA; Yu, J; Zhao, X, 2023) |
| "The elevated aldosterone in primary aldosteronism (PA) is associated with increased insulin resistance and prevalence of diabetes mellitus (DM)." | 1.91 | Diabetes mellitus is associated with more adverse non-hemodynamic left ventricular remodeling and less recovery in patients with primary aldosteronism. ( Chang, CC; Chang, YR; Chang, YY; Chen, UL; Chueh, JS; Huang, KH; Hung, CS; Lai, TS; Lee, BC; Liao, CW; Lin, YH; Lu, CC; Tsai, CH; Wang, SM; Wu, VC, 2023) |
| "Background Primary aldosteronism can cause cardiac dysfunction, including left ventricular hypertrophy, left ventricular diastolic dysfunction, and left atrial enlargement." | 1.72 | Comparison of Echocardiographic Changes Between Surgery and Medication Treatment in Patients With Primary Aldosteronism. ( Hoshino, Y; Inoue, K; Nakai, K; Nishikawa, T; Ono, M; Osada, J; Saito, J; Tsurutani, Y; Ueda, T; Yumoto, K, 2022) |
| "Patients with primary aldosteronism (PA) have cardiac remodeling due to hemodynamic and non-hemodynamic causes." | 1.62 | Hemodynamic and Non-Hemodynamic Components of Cardiac Remodeling in Primary Aldosteronism. ( Chang, CC; Chang, YR; Chang, YY; Chen, YL; Chen, ZW; Hung, CS; Lee, BC; Liao, CW; Lin, LC; Lin, YH; Pan, CT; Tsai, CH; Wu, XM, 2021) |
| "Primary aldosteronism is associated with a higher incidence of left ventricular (LV) hypertrophy and diastolic dysfunction than essential hypertension." | 1.48 | Aldosterone induces left ventricular subclinical systolic dysfunction: a strain imaging study. ( Chang, YY; Chen, CW; Chen, ZW; Huang, KC; Hung, CS; Lee, JK; Liao, CW; Lin, LC; Lin, YH; Wu, VC, 2018) |
| "In patients with KCNJ5-mutated APA, left ventricular hypertrophy was significantly decreased by surgical treatment in patients from either Cured or Improved groups, although those patients with wild-type KCNJ5 showed no change." | 1.48 | KCNJ5 mutation as a predictor for resolution of hypertension after surgical treatment of aldosterone-producing adenoma. ( Kitamoto, T; Nishikawa, T; Omura, M; Saito, J; Suematsu, S, 2018) |
| "Primary aldosteronism (PA) represents the most frequent form of endocrine hypertension." | 1.48 | Cortisol Excess in Patients With Primary Aldosteronism Impacts Left Ventricular Hypertrophy. ( Adolf, C; Arlt, W; Beuschlein, F; Bidlingmaier, M; Franke, A; Heinrich, DA; Köhler, A; Ladurner, R; Lang, K; Löw, A; Reincke, M; Riester, A; Treitl, M, 2018) |
| "HFpEF mice developed hypertension, left ventricular hypertrophy, and diastolic dysfunction and had higher myocardial natriuretic peptide expression." | 1.43 | Heart Failure With Preserved Ejection Fraction Induces Beiging in Adipose Tissue. ( Aprahamian, T; Fuster, JJ; Hulsmans, M; Li, S; Nahrendorf, M; Sam, F; Scherer, PE; Valero-Muñoz, M; Wilson, RM, 2016) |
| "Primary aldosteronism (PA) causes excess left ventricular (LV) hypertrophy and diastolic dysfunction; whether this occurs also in secondary aldosteronism (SA) without hypertension is unknown." | 1.43 | Cardiac Remodeling in Patients With Primary and Secondary Aldosteronism: A Tissue Doppler Study. ( Angeli, P; Cesari, M; Letizia, C; Rosi, S; Rossi, GP; Sciomer, S, 2016) |
| "Aldosterone has hypertrophic and profibrotic effects on the heart." | 1.42 | Plasma aldosterone and left ventricular diastolic function in treatment-naïve patients with hypertension: tissue-Doppler imaging study. ( Catena, C; Kraigher-Krainer, E; Pieske, B; Pilz, S; Sechi, LA; Tomaschitz, A; Verheyen, N, 2015) |
| "Primary aldosteronism (PA), the most frequent form of secondary hypertension, is characterized by a higher rate of cardiovascular (CV) events than essential hypertension (EH)." | 1.40 | Primary aldosteronism and essential hypertension: assessment of cardiovascular risk at diagnosis and after treatment. ( Boscaro, M; Ceccoli, L; di Tizio, V; Giacchetti, G; Ronconi, V; Turchi, F, 2014) |
| "From 257 consecutive primary aldosteronism patients, we identified 176 who had both a diagnosis of APA by the 'four corners' criteria and high-quality echocardiographic data." | 1.40 | KCNJ5 gene somatic mutations affect cardiac remodelling but do not preclude cure of high blood pressure and regression of left ventricular hypertrophy in primary aldosteronism. ( Cesari, M; Cicala, MV; Iacobone, M; Kuppusamy, M; Letizia, C; Mantero, F; Mareso, S; Pessina, AC; Rossi, GP; Sciomer, S; Seccia, TM; Zinnamosca, L, 2014) |
| "Treatment with aldosterone did not alter mitochondrial respiratory function but accelerated Ca(2+)-induced MPT in SSM, but not IFM, compared with healthy old and young beagles." | 1.39 | Enhanced resistance to permeability transition in interfibrillar cardiac mitochondria in dogs: effects of aging and long-term aldosterone infusion. ( Asemu, G; Cox, JW; Dabkowski, ER; Hecker, PA; Hoppel, CL; O'Connell, KA; Rastogi, S; Ribeiro, RF; Sabbah, HN; Shekar, KC; Stanley, WC; Xu, W, 2013) |
| "Enalapril treatment significantly prevented hypertrophy, apoptosis, and CaMKII activity." | 1.38 | Early apoptosis in different models of cardiac hypertrophy induced by high renin-angiotensin system activity involves CaMKII. ( Mattiazzi, A; Palomeque, J; Velez Rueda, JO, 2012) |
| "Hypertension is characterized by left ventricular (LV) hypertrophy (LVH)." | 1.38 | Interferon-γ ablation exacerbates myocardial hypertrophy in diastolic heart failure. ( Baid, S; Garcia, AG; Heo, J; Murthy, NR; Ouchi, N; Sam, F; Wilson, RM, 2012) |
| "Primary aldosteronism (PA) is associated a worse cardiovascular outcome than essential hypertension." | 1.37 | The association of serum potassium level with left ventricular mass in patients with primary aldosteronism. ( Chen, MF; Chien, KL; Chueh, SC; Ho, YL; Huang, KH; Kuo, CC; Lee, JK; Lin, LY; Lin, YH; Liu, KL; Wang, SM; Wang, WJ; Wu, KD; Wu, VC; Yen, RF, 2011) |
| "Spironolactone treatment reversed all the above effects." | 1.37 | A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone. ( Cachofeiro, V; Díez, J; Fortuno, MA; Lahera, V; López-Andrés, N; Martin-Fernandez, B; Rossignol, P; Zannad, F, 2011) |
| "Aldosterone and LVH were investigated in 240 and 110 subjects respectively." | 1.36 | Association of HSD3B1 and HSD3B2 gene polymorphisms with essential hypertension, aldosterone level, and left ventricular structure. ( Aoi, N; Izumi, Y; Matsumoto, K; Nakayama, T; Sato, M; Sato, N; Shimodaira, M; Soma, M, 2010) |
| "The ventricular remodeling of mice were induced by subcutaneous injection of ISO with the dosage of 2 mg/kg daily for 7 d and the rats with L-Thy intraperitoneally with the dosage of 0." | 1.36 | [Effect of Chrysanthemum indicum on ventricular remodeling in rats]. ( Chen, CX; Gao, JP; Gu, WL; Lv, J; Wan, Y; Wu, Q, 2010) |
| "Primary aldosteronism (PA) represents a clinical model useful in assessing the effect of aldosterone increase on LVM." | 1.35 | Inappropriate left ventricular mass in patients with primary aldosteronism. ( Agabiti-Rosei, C; Agabiti-Rosei, E; Aggiusti, C; Belotti, E; Castellano, M; Galbassini, G; Monteduro, C; Muiesan, ML; Paini, A; Rizzoni, D; Salvetti, M, 2008) |
| " RI was compared to the ARB, candesartan (3 mg/kg/day PO), and to the ACEI, enalapril (60 mg/kg/day PO) in a 4-week dosing paradigm." | 1.35 | A nonpeptide, piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes. ( Carlson, T; Kowala, MC; Leadley, R; Major, TC; Okerberg, C; Olszewski, B; Ostroski, R; Rosebury, W; Schroeder, R, 2008) |
| "To evaluate the prevalence of left ventricular hypertrophy (LVH) and left ventricular geometry in a group of 293 hypertensive patients with stage 2-5 chronic kidney disease (CKD), compared with 289 essential hypertensive patients with normal renal function." | 1.35 | Left ventricular hypertrophy and geometry in hypertensive patients with chronic kidney disease. ( Cerasola, G; Cottone, S; Cusimano, P; Mulè, G; Nardi, E; Palermo, A, 2009) |
| "Primary aldosteronism (PA) is caused by autonomous hypersecretion of aldosterone from the adrenal cortex, classically from an adenoma, resulting in sodium and water retention, hypokalaemia and raised blood pressure." | 1.35 | Atrial fibrillation in primary aldosteronism. ( Beevers, DG; Karthikeyan, VJ; Lip, GY; Watson, T, 2009) |
| "The aldosterone level was comparable in both groups." | 1.35 | Diastolic dysfunction is associated with insulin resistance, but not with aldosterone level in normotensive offspring of hypertensive families. ( Poredos, P; Trojar, A; Zeljko, T; Zizek, B, 2008) |
| "Fifty-four patients with primary aldosteronism were enrolled in a prospective study and were followed for a mean of 6." | 1.34 | Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. ( Catena, C; Chiuch, A; Colussi, G; Gianfagna, P; Lapenna, R; Nadalini, E; Sechi, LA, 2007) |
| "Myocardial hypertrophy ventricular remodeling model was induced by abdominal aortic banding (AAB) in rats." | 1.34 | [Influnce of Tinglizi on some neuroendocrine factors and type I and III collagen in ventricular remodeling induced by abdominal aortic banding in rats]. ( Chen, CX; Guo, J, 2007) |
| "A total of 25 patients with primary aldosteronism caused by Conn's adenoma, 29 patients with renovascular hypertension, and 29 patients with essential hypertension (EHT) were included in the present study." | 1.33 | Role of aldosterone in left ventricular hypertrophy in hypertension. ( Fujii, K; Iida, M; Matsumura, K; Oka, M; Oniki, H, 2006) |
| "Left ventricular hypertrophy was present in 60% of patients." | 1.32 | The role of biochemical tests and clinical symptoms in differential diagnosis of primary aldosteronism. ( Cybulska, I; Dobrucki, T; Janas, J; Janaszek-Sitkowska, H; Januszkiewicz, A; Kabat, M; Makowiecka-Cieśla, M; Peczkowska, M; Postuła, M; Prejbisz, A, 2003) |
| "Aldosterone plays an important role in development of left ventricular (LV) hypertrophy and myocardial fibrosis." | 1.32 | Association of -344/T/C aldosterone synthase polymorphism (CYP11B2) with left ventricular structure and humoral parameters in young normotensive men. ( Aschermann, M; Heller, S; Hlubocká, Z; Horký, K; Jáchymová, M; Jindra, A; Linhart, A; Peleska, J; Umnerová, V, 2004) |
| "Primary hyperaldosteronism is a well-recognized cause of secondary hypertension." | 1.32 | Serum aldosterone and the incidence of hypertension in nonhypertensive persons. ( Benjamin, EJ; Evans, JC; Larson, MG; Levy, D; Meigs, JB; Rifai, N; Vasan, RS; Wilson, PW, 2004) |
| "In patients with untreated hypertension, there is evidence of increased collagen synthesis, degradation, and inhibition of degradation resulting in fibrosis." | 1.31 | TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. ( Dunn, FG; Lindsay, MM; Maxwell, P, 2002) |
| "Enrasentan-treated groups exhibited significantly improved survival (90-95% vs." | 1.31 | Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunction. ( Aiyar, N; Anderson, KM; Barone, FC; Coatney, RW; Nelson, AH; Ohlstein, EH; Olzinski, AR; Willette, RN; Woods, T, 2001) |
| "Men with left ventricular hypertrophy presented with significantly higher serum ACE concentrations than those with normal left ventricular mass index (P = 0." | 1.30 | Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass. ( Danser, AH; Hense, HW; Kürzinger, S; Luchner, A; Muscholl, M; Riegger, GA; Schunkert, H, 1997) |
| "In contrast, left ventricular hypertrophy markedly progressed despite the mild extracardiac target-organ damage in primary aldosteronism." | 1.30 | Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism. ( Hamada, M; Hara, Y; Hayashi, Y; Hiwada, K; Kodama, K; Kohara, K; Okayama, H; Shigematsu, Y, 1997) |
| "The results suggest that left ventricular hypertrophy is more pronounced in patients with primary aldosteronism than in patients with other forms of hypertension." | 1.30 | Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension. ( Demura, H; Demura, R; Hase, M; Naruse, K; Naruse, M; Seki, T; Tanabe, A; Tanaka, M; Yoshimoto, T, 1997) |
| "Aldosterone-salt treatment induced, (1) arterial hypertension (+40%) and LV hypertrophy (+60%) without altering LV-fractional shortening, (2) an increase in plasma norepinephrine levels (+262%) and suppression of renin activity." | 1.30 | Modifications of myocardial Na+,K(+)-ATPase isoforms and Na+/Ca2+ exchanger in aldosterone/salt-induced hypertension in guinea pigs. ( Carayon, A; Charlemagne, D; Lechat, P; Mougenot, N; Ramírez-Gil, JF; Trouvé, P, 1998) |
| "Cardiac fibrosis is linked to aldosterone-induced hypertension, but the effects on in vivo left ventricular (LV) function are not established." | 1.30 | In vivo left ventricular function and collagen expression in aldosterone/salt-induced hypertension. ( Charlemagne, D; Delcayre, C; Lechat, P; Mougenot, N; Ramirez-Gil, JF; Robert, V; Trouve, P; Wassef, M, 1998) |
| "Patients with newly discovered, never-treated, sustained hypertension were included in the study after a 1 month run-in, during which time their blood pressure was measured three times at 2 week intervals." | 1.30 | Clinic-daytime blood pressure difference and cardiovascular damage. ( Celentano, A; Crivaro, M; Ferrara, LA; Gaeta, I; Guida, L; Iannuzzi, R; Marotta, T; Pasanisi, F, 1999) |
| "To study severity of left ventricular hypertrophy (LVH) and left ventricular function in patients with primary aldosteronism (PA) in comparison with hyperaldosteronemia and preoperative arterial hypertension, to follow the dynamics of these parameters early and late after surgical removal of aldosteroma." | 1.30 | [Left ventricular myocardial structure and function in patients with primary aldosteronism]. ( Arabidze, GG; Chikhladze, NM; Iarovaia, EB; Sergakova, LM, 1999) |
| "The degree of hyperaldosteronism in the subjects was mild compared with other conditions and, although an effect on left ventricular mass index could be detected, the present results indicate that other factors may be necessary for the development of left ventricular hypertrophy." | 1.29 | Left ventricular mass in hereditary human hypertension: glucocorticoid-suppressible hyperaldosteronism. ( Connell, JM; Jamieson, A; Kennedy, JA; Murdoch, D, 1995) |
| "Aldosterone has been associated with the development of cardiac hypertrophy and a correlation has been found between levels of aldosterone and the degree of cardiac hypertrophy in hypertensive patients." | 1.29 | Aldosterone levels and cardiac hypertrophy in professional cyclists. ( Barriales, R; Cortina, A; González, V; Iglesias Cubero, G; Rodriguez Reguero, JJ; Terrados, N, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 39 (24.38) | 18.2507 |
| 2000's | 56 (35.00) | 29.6817 |
| 2010's | 56 (35.00) | 24.3611 |
| 2020's | 9 (5.63) | 2.80 |
| Authors | Studies |
|---|---|
| Ueda, T | 2 |
| Tsurutani, Y | 1 |
| Osada, J | 1 |
| Inoue, K | 1 |
| Hoshino, Y | 1 |
| Ono, M | 1 |
| Nakai, K | 1 |
| Saito, J | 2 |
| Yumoto, K | 1 |
| Nishikawa, T | 2 |
| Al-Hashedi, EM | 1 |
| Zhao, X | 1 |
| Mohammed, AA | 1 |
| Juvenal, H | 1 |
| Yu, J | 1 |
| Chen, UL | 1 |
| Liao, CW | 3 |
| Wang, SM | 2 |
| Lai, TS | 1 |
| Huang, KH | 2 |
| Chang, CC | 2 |
| Lee, BC | 2 |
| Lu, CC | 1 |
| Chang, YR | 2 |
| Chang, YY | 5 |
| Hung, CS | 5 |
| Chueh, JS | 1 |
| Wu, VC | 6 |
| Tsai, CH | 3 |
| Lin, YH | 7 |
| Sun, Z | 1 |
| Chen, Z | 1 |
| Liu, R | 1 |
| Lu, G | 1 |
| Li, Z | 1 |
| Sun, Y | 1 |
| Mandal, C | 1 |
| Dutta, PK | 1 |
| Tu, W | 1 |
| Pratt, JH | 2 |
| Liu, Y | 3 |
| Lin, Y | 1 |
| Zhang, MM | 1 |
| Li, XH | 1 |
| Liu, YY | 1 |
| Zhao, J | 1 |
| Shi, L | 1 |
| Pan, CT | 2 |
| Chen, ZW | 3 |
| Wu, XM | 3 |
| Chen, YL | 1 |
| Lin, LC | 3 |
| Huang, KC | 1 |
| Lee, JK | 4 |
| Chen, CW | 1 |
| Kitamoto, T | 1 |
| Omura, M | 1 |
| Suematsu, S | 1 |
| Cannone, V | 1 |
| Buglioni, A | 1 |
| Sangaralingham, SJ | 1 |
| Scott, C | 1 |
| Bailey, KR | 1 |
| Rodeheffer, R | 1 |
| Redfield, MM | 1 |
| Sarzani, R | 1 |
| Burnett, JC | 1 |
| Adolf, C | 1 |
| Köhler, A | 1 |
| Franke, A | 1 |
| Lang, K | 1 |
| Riester, A | 1 |
| Löw, A | 1 |
| Heinrich, DA | 1 |
| Bidlingmaier, M | 1 |
| Treitl, M | 1 |
| Ladurner, R | 1 |
| Beuschlein, F | 1 |
| Arlt, W | 1 |
| Reincke, M | 1 |
| Fujii, H | 1 |
| Watanabe, K | 1 |
| Kono, K | 1 |
| Goto, S | 1 |
| Watanabe, S | 1 |
| Nishi, S | 1 |
| Stanley, WC | 2 |
| Cox, JW | 2 |
| Asemu, G | 2 |
| O'Connell, KA | 2 |
| Dabkowski, ER | 2 |
| Xu, W | 2 |
| Ribeiro, RF | 2 |
| Shekar, KC | 2 |
| Hoag, SW | 1 |
| Rastogi, S | 2 |
| Sabbah, HN | 2 |
| Daneault, C | 1 |
| des Rosiers, C | 1 |
| Zhang, Y | 2 |
| Shao, L | 1 |
| Ma, A | 1 |
| Guan, G | 1 |
| Wang, J | 3 |
| Wang, Y | 2 |
| Tian, G | 1 |
| Zhang, YJ | 1 |
| Li, NF | 1 |
| Zhang, JH | 1 |
| Xing, WH | 1 |
| Li, B | 1 |
| Ho, YL | 3 |
| Chueh, SC | 3 |
| Changh, YS | 1 |
| Yang, SY | 1 |
| Hu, YH | 1 |
| Sui, MJ | 1 |
| Chen, MF | 2 |
| Wu, KD | 3 |
| Peer, M | 1 |
| Mashavi, M | 1 |
| Matas, Z | 1 |
| Harpaz, D | 1 |
| Shargorodsky, M | 1 |
| Turchi, F | 1 |
| Ronconi, V | 1 |
| di Tizio, V | 1 |
| Ceccoli, L | 1 |
| Boscaro, M | 1 |
| Giacchetti, G | 1 |
| Anagnostis, P | 1 |
| Katsiki, N | 1 |
| Athyros, VG | 1 |
| Karagiannis, A | 1 |
| Rossi, GP | 5 |
| Cesari, M | 2 |
| Letizia, C | 2 |
| Seccia, TM | 1 |
| Cicala, MV | 1 |
| Zinnamosca, L | 1 |
| Kuppusamy, M | 1 |
| Mareso, S | 1 |
| Sciomer, S | 2 |
| Iacobone, M | 1 |
| Mantero, F | 1 |
| Pessina, AC | 3 |
| Azizi, M | 1 |
| Perdrix, L | 1 |
| Bobrie, G | 1 |
| Frank, M | 1 |
| Chatellier, G | 2 |
| Ménard, J | 1 |
| Plouin, PF | 2 |
| Mulè, G | 3 |
| Nardi, E | 3 |
| Guarino, L | 1 |
| Cacciatore, V | 1 |
| Geraci, G | 1 |
| Calcaterra, I | 1 |
| Oddo, B | 1 |
| Vaccaro, F | 1 |
| Cottone, S | 3 |
| Cuspidi, C | 1 |
| Tadic, M | 1 |
| Sala, C | 1 |
| Catena, C | 6 |
| Verheyen, N | 1 |
| Pilz, S | 3 |
| Kraigher-Krainer, E | 2 |
| Tomaschitz, A | 3 |
| Sechi, LA | 6 |
| Pieske, B | 3 |
| Ritter, AM | 1 |
| Fontana, V | 1 |
| Faria, AP | 1 |
| Modolo, R | 1 |
| Barbaro, NR | 1 |
| Sabbatini, AR | 1 |
| Peres, H | 1 |
| Biagi, C | 1 |
| Silva, PS | 1 |
| Lopes, PC | 1 |
| Tanus-Santos, JE | 1 |
| Coelho, EB | 1 |
| Moreno, H | 2 |
| Feniman-De-Stefano, GM | 1 |
| Zanati-Basan, SG | 2 |
| De Stefano, LM | 2 |
| Xavier, PS | 2 |
| Castro, AD | 1 |
| Caramori, JC | 2 |
| Barretti, P | 2 |
| Franco, RJ | 1 |
| Martin, LC | 2 |
| Verheyen, ND | 1 |
| Url-Michitsch, M | 1 |
| Colussi, G | 4 |
| Valero-Muñoz, M | 1 |
| Li, S | 1 |
| Wilson, RM | 2 |
| Hulsmans, M | 1 |
| Aprahamian, T | 1 |
| Fuster, JJ | 1 |
| Nahrendorf, M | 1 |
| Scherer, PE | 1 |
| Sam, F | 3 |
| Sezai, A | 2 |
| Osaka, S | 1 |
| Yaoita, H | 1 |
| Arimoto, M | 1 |
| Hata, H | 1 |
| Shiono, M | 2 |
| Sakino, H | 1 |
| Feniman De Stefano, GM | 1 |
| Silva, VR | 1 |
| da Silva Franco, RJ | 1 |
| Angeli, P | 1 |
| Rosi, S | 1 |
| Xanthakis, V | 1 |
| Enserro, DM | 1 |
| Larson, MG | 2 |
| Wollert, KC | 1 |
| Januzzi, JL | 1 |
| Levy, D | 2 |
| Aragam, J | 1 |
| Benjamin, EJ | 2 |
| Cheng, S | 1 |
| Wang, TJ | 1 |
| Mitchell, GF | 1 |
| Vasan, RS | 2 |
| Cusimano, P | 2 |
| Seddio, G | 1 |
| Geraci, C | 1 |
| Palermo, A | 2 |
| Andronico, G | 1 |
| Cerasola, G | 2 |
| Graf, K | 1 |
| Hucko, T | 1 |
| Stawowy, P | 1 |
| Díez, J | 2 |
| Muiesan, ML | 2 |
| Salvetti, M | 2 |
| Paini, A | 1 |
| Agabiti-Rosei, C | 1 |
| Monteduro, C | 2 |
| Galbassini, G | 1 |
| Belotti, E | 1 |
| Aggiusti, C | 1 |
| Rizzoni, D | 2 |
| Castellano, M | 2 |
| Agabiti-Rosei, E | 2 |
| Major, TC | 1 |
| Olszewski, B | 1 |
| Rosebury, W | 1 |
| Okerberg, C | 1 |
| Carlson, T | 1 |
| Ostroski, R | 1 |
| Schroeder, R | 1 |
| Kowala, MC | 1 |
| Leadley, R | 1 |
| Karabayeva, AZh | 1 |
| Esaian, AM | 1 |
| Kayukov, IG | 1 |
| Parastaeva, MM | 1 |
| Beresneva, ON | 1 |
| Kotenko, LV | 1 |
| Sevastyanova, IE | 1 |
| Tsutamoto, T | 2 |
| Tanaka, T | 1 |
| Nishiyama, K | 2 |
| Yamaji, M | 2 |
| Kawahara, C | 2 |
| Fujii, M | 2 |
| Yamamoto, T | 2 |
| Horie, M | 2 |
| Jansen, PM | 1 |
| Danser, AH | 2 |
| Imholz, BP | 1 |
| van den Meiracker, AH | 1 |
| Ubaid-Girioli, S | 1 |
| Adriana de Souza, L | 1 |
| Yugar-Toledo, JC | 1 |
| Martins, LC | 1 |
| Ferreira-Melo, S | 1 |
| Coelho, OR | 1 |
| Sierra, C | 1 |
| Coca, A | 2 |
| Pimenta, E | 1 |
| Kotchen, TA | 2 |
| Jin, Y | 2 |
| Kuznetsova, T | 2 |
| Maillard, M | 1 |
| Richart, T | 1 |
| Thijs, L | 2 |
| Bochud, M | 1 |
| Herregods, MC | 1 |
| Burnier, M | 1 |
| Fagard, R | 2 |
| Staessen, JA | 2 |
| Watson, T | 1 |
| Karthikeyan, VJ | 1 |
| Lip, GY | 1 |
| Beevers, DG | 1 |
| Shi, H | 1 |
| Ma, C | 1 |
| Zhou, J | 1 |
| Hu, Z | 1 |
| Wu, D | 1 |
| Gao, JP | 2 |
| Chen, CX | 3 |
| Gu, WL | 2 |
| Wu, Q | 2 |
| Lü, J | 1 |
| Shimodaira, M | 1 |
| Nakayama, T | 1 |
| Sato, N | 1 |
| Aoi, N | 1 |
| Sato, M | 1 |
| Izumi, Y | 1 |
| Soma, M | 2 |
| Matsumoto, K | 1 |
| Di Fabio, A | 1 |
| du Cailar, G | 1 |
| Fesler, P | 1 |
| Ribstein, J | 1 |
| Mimran, A | 1 |
| Yoshida, C | 1 |
| Goda, A | 1 |
| Naito, Y | 1 |
| Nakaboh, A | 1 |
| Matsumoto, M | 1 |
| Otsuka, M | 1 |
| Ohyanagi, M | 1 |
| Hirotani, S | 1 |
| Lee-Kawabata, M | 1 |
| Tsujino, T | 1 |
| Masuyama, T | 1 |
| Wan, Y | 1 |
| Lv, J | 1 |
| He, LC | 1 |
| Duan, HJ | 1 |
| Zhan, YZ | 1 |
| Kuo, CC | 1 |
| Yen, RF | 1 |
| Liu, KL | 1 |
| Wang, WJ | 1 |
| Lin, LY | 1 |
| Chien, KL | 1 |
| Bernini, G | 1 |
| Bacca, A | 1 |
| Carli, V | 1 |
| Carrara, D | 1 |
| Materazzi, G | 1 |
| Berti, P | 1 |
| Miccoli, P | 1 |
| Pisano, R | 1 |
| Tantardini, V | 1 |
| Bernini, M | 1 |
| Taddei, S | 1 |
| Pouleur, AC | 2 |
| Uno, H | 1 |
| Prescott, MF | 1 |
| Desai, A | 1 |
| Appelbaum, E | 2 |
| Lukashevich, V | 1 |
| Smith, BA | 1 |
| Dahlöf, B | 2 |
| Solomon, SD | 2 |
| Edelmann, F | 1 |
| Wachter, R | 1 |
| Gelbrich, G | 1 |
| Knoke, M | 1 |
| Düngen, HD | 1 |
| Binder, L | 1 |
| Stahrenberg, R | 1 |
| Schmidt, A | 1 |
| März, W | 1 |
| Hata, M | 1 |
| Yoshitake, I | 1 |
| Unosawa, S | 1 |
| Wakui, S | 1 |
| López-Andrés, N | 1 |
| Martin-Fernandez, B | 1 |
| Rossignol, P | 1 |
| Zannad, F | 1 |
| Lahera, V | 1 |
| Fortuno, MA | 1 |
| Cachofeiro, V | 1 |
| Guo, P | 1 |
| Wu, C | 1 |
| Masaki, T | 1 |
| Mori, H | 1 |
| Nishiyama, A | 1 |
| Schmitz, B | 1 |
| Asayama, K | 1 |
| Brand, SM | 1 |
| Heymans, S | 1 |
| Brand, E | 1 |
| Colussi, GL | 1 |
| Marzano, L | 1 |
| McQuarrie, EP | 1 |
| Freel, EM | 1 |
| Mark, PB | 1 |
| Fraser, R | 1 |
| Patel, RK | 1 |
| Dargie, HG | 1 |
| Connell, JM | 2 |
| Jardine, AG | 1 |
| Pitt, B | 2 |
| Vardeny, O | 1 |
| Takeuchi, M | 1 |
| Verma, A | 1 |
| Prescott, M | 1 |
| Smith, B | 1 |
| Yano, H | 1 |
| Hibi, K | 1 |
| Nozawa, N | 1 |
| Ozaki, H | 1 |
| Kusama, I | 1 |
| Ebina, T | 1 |
| Kosuge, M | 1 |
| Tsukahara, K | 1 |
| Okuda, J | 1 |
| Morita, S | 1 |
| Umemura, S | 1 |
| Kimura, K | 1 |
| Velez Rueda, JO | 1 |
| Palomeque, J | 1 |
| Mattiazzi, A | 1 |
| Lee, HH | 1 |
| Liu, YC | 1 |
| Chang, HW | 1 |
| Lin, CY | 1 |
| Lo, MT | 1 |
| Garcia, AG | 1 |
| Heo, J | 1 |
| Murthy, NR | 1 |
| Baid, S | 1 |
| Ouchi, N | 1 |
| Zhang, M | 1 |
| Perino, A | 1 |
| Ghigo, A | 1 |
| Hirsch, E | 1 |
| Shah, AM | 1 |
| Burns, J | 1 |
| Ball, SG | 1 |
| Worthy, G | 1 |
| Struthers, AD | 2 |
| Mary, DA | 1 |
| Greenwood, JP | 1 |
| Peng, F | 1 |
| Lin, J | 1 |
| Lin, L | 1 |
| Tang, H | 1 |
| Murro, DG | 1 |
| Beavers, M | 1 |
| Harshfield, GA | 1 |
| Kapuku, GK | 1 |
| Hecker, PA | 1 |
| Hoppel, CL | 1 |
| Valeri, M | 1 |
| Porteri, E | 1 |
| Guelfi, D | 1 |
| Garavelli, G | 1 |
| Lindsay, MM | 1 |
| Maxwell, P | 1 |
| Dunn, FG | 1 |
| Malmqvist, K | 2 |
| Wallén, HN | 1 |
| Held, C | 1 |
| Kahan, T | 2 |
| Olsen, MH | 1 |
| Wachtell, K | 1 |
| Hermann, KL | 1 |
| Frandsen, E | 1 |
| Dige-Petersen, H | 1 |
| Rokkedal, J | 1 |
| Devereux, RB | 1 |
| Ibsen, H | 1 |
| Varagic, J | 1 |
| Frohlich, ED | 1 |
| Suzuki, M | 1 |
| Hamada, M | 3 |
| Yamamoto, K | 1 |
| Kazatani, Y | 1 |
| Hiwada, K | 3 |
| Delles, C | 2 |
| Schmidt, BM | 1 |
| Müller, HJ | 1 |
| Oehmer, S | 1 |
| Klingbeil, AU | 1 |
| Schmieder, RE | 3 |
| Buikema, H | 2 |
| Han, S | 1 |
| Zheng, Z | 1 |
| Ren, D | 1 |
| Wang, X | 1 |
| Nishikimi, T | 2 |
| Akimoto, K | 1 |
| Tadokoro, K | 1 |
| Mori, Y | 1 |
| Minamino, N | 1 |
| Prejbisz, A | 1 |
| Postuła, M | 1 |
| Cybulska, I | 1 |
| Dobrucki, T | 1 |
| Kabat, M | 1 |
| Peczkowska, M | 1 |
| Janas, J | 1 |
| Janaszek-Sitkowska, H | 1 |
| Makowiecka-Cieśla, M | 1 |
| Januszkiewicz, A | 1 |
| Guo, H | 2 |
| Cheng, J | 1 |
| Lee, JD | 1 |
| Shan, J | 1 |
| Matsui, Y | 1 |
| Jia, N | 1 |
| Okamoto, H | 1 |
| Kon, S | 1 |
| Onozuka, H | 1 |
| Akino, M | 1 |
| Liu, L | 1 |
| Morimoto, J | 1 |
| Rittling, SR | 1 |
| Denhardt, D | 1 |
| Kitabatake, A | 1 |
| Uede, T | 1 |
| Heller, S | 1 |
| Linhart, A | 1 |
| Jindra, A | 1 |
| Jáchymová, M | 1 |
| Horký, K | 1 |
| Peleska, J | 1 |
| Hlubocká, Z | 1 |
| Umnerová, V | 1 |
| Aschermann, M | 1 |
| Evans, JC | 1 |
| Wilson, PW | 1 |
| Meigs, JB | 1 |
| Rifai, N | 1 |
| Gumieniak, O | 1 |
| Williams, GH | 2 |
| Williams, JS | 1 |
| Jeunemaitre, X | 1 |
| Hopkins, PN | 1 |
| Conlin, PR | 1 |
| Soylu, A | 1 |
| Temizhan, A | 1 |
| Duzenli, MA | 1 |
| Sokmen, G | 1 |
| Koylu, O | 1 |
| Telli, HH | 1 |
| Glorioso, N | 1 |
| Filigheddu, F | 1 |
| Parpaglia, PP | 1 |
| Soro, A | 1 |
| Troffa, C | 1 |
| Argiolas, G | 1 |
| Mulatero, P | 1 |
| Westendorp, B | 1 |
| Schoemaker, RG | 1 |
| Boomsma, F | 1 |
| van Veldhuisen, DJ | 1 |
| van Gilst, WH | 1 |
| Coca, SG | 1 |
| Perazella, MA | 1 |
| Matsumura, K | 1 |
| Fujii, K | 1 |
| Oniki, H | 1 |
| Oka, M | 1 |
| Iida, M | 1 |
| Stewart, AD | 1 |
| Millasseau, SC | 1 |
| Dawes, M | 1 |
| Kyd, PA | 1 |
| Chambers, JB | 1 |
| Ritter, JM | 1 |
| Chowienczyk, PJ | 1 |
| Taniguchi, I | 1 |
| Kawai, M | 1 |
| Date, T | 1 |
| Yoshida, S | 1 |
| Seki, S | 1 |
| Taniguchi, M | 1 |
| Shimizu, M | 1 |
| Mochizuki, S | 1 |
| Steigerwalt, S | 1 |
| Zafar, A | 1 |
| Mesiha, N | 1 |
| Gardin, J | 1 |
| Provenzano, R | 1 |
| Bomback, AS | 1 |
| Klemmer, PJ | 1 |
| Nakahara, T | 1 |
| Takata, Y | 1 |
| Hirayama, Y | 1 |
| Asano, K | 1 |
| Adachi, H | 1 |
| Shiokawa, G | 1 |
| Sumi, T | 1 |
| Ogawa, T | 1 |
| Yamashina, A | 1 |
| Strand, AH | 1 |
| Gudmundsdottir, H | 1 |
| Fossum, E | 1 |
| Os, I | 1 |
| Bjørnerheim, R | 1 |
| Kjeldsen, SE | 1 |
| Lebrasseur, NK | 1 |
| Duhaney, TA | 1 |
| De Silva, DS | 1 |
| Cui, L | 1 |
| Ip, PC | 1 |
| Joseph, L | 1 |
| Lapenna, R | 1 |
| Nadalini, E | 1 |
| Chiuch, A | 1 |
| Gianfagna, P | 1 |
| Guo, J | 1 |
| Zizek, B | 1 |
| Poredos, P | 1 |
| Trojar, A | 1 |
| Zeljko, T | 1 |
| Robert, V | 3 |
| Silvestre, JS | 1 |
| Charlemagne, D | 3 |
| Sabri, A | 1 |
| Trouvé, P | 3 |
| Wassef, M | 2 |
| Swynghedauw, B | 2 |
| Delcayre, C | 3 |
| Jamieson, A | 1 |
| Murdoch, D | 1 |
| Kennedy, JA | 1 |
| Cichocka, E | 1 |
| Wyszyńska, T | 1 |
| Januszewicz, P | 1 |
| Kawalec, W | 1 |
| Shigematsu, Y | 2 |
| Mukai, M | 1 |
| Matsuoka, H | 1 |
| Sumimoto, T | 1 |
| Besse, S | 1 |
| Van Thiem, N | 1 |
| Young, M | 1 |
| Fullerton, M | 1 |
| Dilley, R | 1 |
| Funder, J | 1 |
| Navarro-Lopez, F | 1 |
| Pare, JC | 1 |
| De La Sierra, A | 1 |
| Bosch, X | 1 |
| Urbano Marquez, A | 1 |
| Denolle, T | 1 |
| Julien, J | 1 |
| Battaglia, C | 1 |
| Luo, P | 1 |
| Duprez, DA | 1 |
| Bauwens, FR | 1 |
| De Buyzere, ML | 1 |
| De Backer, TL | 1 |
| Kaufman, JM | 1 |
| Van Hoecke, J | 1 |
| Vermeulen, A | 1 |
| Clement, DL | 1 |
| Zhu, YC | 1 |
| Zhu, YZ | 1 |
| Spitznagel, H | 1 |
| Gohlke, P | 1 |
| Unger, T | 1 |
| Iglesias Cubero, G | 1 |
| Rodriguez Reguero, JJ | 1 |
| Terrados, N | 1 |
| González, V | 1 |
| Barriales, R | 1 |
| Cortina, A | 1 |
| Schroeder, AP | 1 |
| Sihm, I | 1 |
| Mørn, B | 1 |
| Thygesen, K | 1 |
| Pedersen, EB | 1 |
| Lederballe, O | 1 |
| Kobayashi, S | 1 |
| Yano, M | 1 |
| Kohno, M | 1 |
| Obayashi, M | 1 |
| Hisamatsu, Y | 1 |
| Ryoke, T | 1 |
| Ohkusa, T | 1 |
| Yamakawa, K | 1 |
| Matsuzaki, M | 1 |
| Schunkert, H | 3 |
| Hense, HW | 3 |
| Muscholl, M | 1 |
| Luchner, A | 2 |
| Kürzinger, S | 2 |
| Riegger, GA | 3 |
| Okayama, H | 1 |
| Hara, Y | 1 |
| Hayashi, Y | 1 |
| Kodama, K | 1 |
| Kohara, K | 1 |
| Vallotton, MB | 1 |
| Braconi-Quintaje, S | 1 |
| Lang, U | 1 |
| Lerch, R | 1 |
| Montessuit, C | 1 |
| Tanabe, A | 1 |
| Naruse, M | 1 |
| Naruse, K | 1 |
| Hase, M | 1 |
| Yoshimoto, T | 1 |
| Tanaka, M | 1 |
| Seki, T | 1 |
| Demura, R | 1 |
| Demura, H | 1 |
| Mervaala, EM | 1 |
| Malmberg, L | 1 |
| Teräväinen, TL | 1 |
| Lähteenmäki, T | 1 |
| Karjala, K | 1 |
| Paakkari, I | 1 |
| Pörsti, I | 1 |
| Mest, HJ | 1 |
| Vapaatalo, H | 1 |
| Karppanen, H | 1 |
| Hui, Y | 1 |
| Hao, Y | 1 |
| Chen, X | 1 |
| Jing, S | 1 |
| Dai, Z | 1 |
| Ueno, H | 1 |
| Takata, M | 1 |
| Tomita, S | 1 |
| Oh-hashi, S | 1 |
| Yasumoto, K | 1 |
| Inoue, H | 1 |
| Vallés Belsué, F | 1 |
| Anguita Sánchez, M | 1 |
| Sacchetto, A | 2 |
| Muscholl, MW | 2 |
| Muders, F | 1 |
| Elsner, D | 1 |
| Kuch, B | 1 |
| Phillips, RA | 1 |
| Diamond, JA | 1 |
| Gharavi, A | 1 |
| Schlaich, MP | 2 |
| Schobel, HP | 2 |
| Langenfeld, MR | 1 |
| Hilgers, K | 1 |
| Ramírez-Gil, JF | 2 |
| Mougenot, N | 2 |
| Carayon, A | 1 |
| Lechat, P | 2 |
| Vantrimpont, P | 1 |
| Rouleau, JL | 1 |
| Ciampi, A | 1 |
| Harel, F | 1 |
| de Champlain, J | 1 |
| Bichet, D | 1 |
| Moyé, LA | 1 |
| Pfeffer, M | 1 |
| Pavan, E | 1 |
| Scognamiglio, R | 1 |
| Pietra, M | 1 |
| Guida, L | 1 |
| Iannuzzi, R | 1 |
| Crivaro, M | 1 |
| Gaeta, I | 1 |
| Pasanisi, F | 1 |
| Celentano, A | 1 |
| Marotta, T | 1 |
| Ferrara, LA | 1 |
| Sato, A | 2 |
| Suzuki, Y | 1 |
| Saruta, T | 2 |
| Hengstenberg, C | 1 |
| Holmer, SR | 1 |
| Broeckel, U | 1 |
| Döring, A | 1 |
| Jacobi, J | 1 |
| Morimoto, A | 1 |
| Yoshihara, F | 1 |
| Horio, T | 1 |
| Nagaya, N | 1 |
| Matsuo, H | 1 |
| Dohi, K | 1 |
| Kangawa, K | 1 |
| Funder, JW | 1 |
| Arabidze, GG | 1 |
| Chikhladze, NM | 1 |
| Sergakova, LM | 1 |
| Iarovaia, EB | 1 |
| Hirano, S | 1 |
| Imamura, T | 1 |
| Matsuo, T | 1 |
| Ishiyama, Y | 1 |
| Kato, J | 1 |
| Kitamura, K | 1 |
| Koiwaya, Y | 1 |
| Eto, T | 1 |
| Tozawa, M | 1 |
| Takishita, S | 1 |
| Muratani, H | 1 |
| Fukiyama, K | 1 |
| El-Gharbawy, AH | 1 |
| Nadig, VS | 1 |
| Kotchen, JM | 1 |
| Grim, CE | 1 |
| Sagar, KB | 1 |
| Kaldunski, M | 1 |
| Hamet, P | 1 |
| Pausova, Z | 1 |
| Gaudet, D | 1 |
| Gossard, F | 1 |
| Willette, RN | 1 |
| Anderson, KM | 1 |
| Nelson, AH | 1 |
| Olzinski, AR | 1 |
| Woods, T | 1 |
| Coatney, RW | 1 |
| Aiyar, N | 1 |
| Ohlstein, EH | 1 |
| Barone, FC | 1 |
| Lu, D | 1 |
| He, H | 1 |
| Zhou, B | 1 |
| Jiang, C | 1 |
| Kurland, L | 1 |
| Melhus, H | 1 |
| Karlsson, J | 1 |
| Ohman, P | 1 |
| Nyström, F | 1 |
| Hägg, A | 1 |
| Lind, L | 1 |
| Miya, Y | 1 |
| Sumino, H | 1 |
| Ichikawa, S | 1 |
| Nakamura, T | 1 |
| Kanda, T | 1 |
| Kumakura, H | 1 |
| Takayama, Y | 1 |
| Mizunuma, H | 1 |
| Sakamaki, T | 1 |
| Kurabayashi, M | 1 |
| Selivonenko, VG | 1 |
| Sholokh, SG | 1 |
| Morozov, AI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Mineralcorticoid Recept Antagonist on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia：A Multicenter Randomized Controlled Study[NCT05688579] | Phase 4 | 8,000 participants (Anticipated) | Interventional | 2023-04-16 | Enrolling by invitation | ||
| A Safety and Feasibility Study of Water-only Fasting and Refeeding for Treatment of Stage 1 and 2 Hypertensive Patients[NCT04515095] | 30 participants (Actual) | Interventional | 2020-08-16 | Completed | |||
| Assessment of the Effects of the Combination of Spironolactone to Conventional Pharmacotherapy in Dialysis Patients[NCT01128101] | Phase 4 | 60 participants (Anticipated) | Interventional | 2011-03-31 | Recruiting | ||
| Prospective Assessment of The Prevalence of Primary Aldosteronism in Hypertensive Patients Presenting With Atrial Flutter or Fibrillation[NCT01267747] | 411 participants (Actual) | Observational | 2015-01-31 | Completed | |||
| A 36-week, Randomized, Double-blind, Multi-center, Parallel Group Study Comparing the Efficacy and Safety of Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essentia[NCT00219141] | Phase 3 | 460 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Left ventricular mass index (LVMI) was measured by magnetic resonance imaging (MRI). An increase in LVMI indicates hypertrophy of the left ventricle. This could be a normal reversible response to cardiovascular conditioning (athletic heart) or an abnormal irreversible response to chronically increased volume load (preload) or increased pressure load (afterload). Thickening of the ventricular muscle results in increased left ventricular pressure, increased end-systolic volume, and decreased end-diastolic volume, causing an overall reduction in cardiac output. (NCT00219141)
Timeframe: Baseline to end of study (Week 36)
| Intervention | g/m^2 (Least Squares Mean) |
|---|---|
| Aliskiren 300 mg | -5.51 |
| Losartan 100 mg | -4.81 |
| Aliskiren/Losartan 300/100 mg | -5.61 |
(NCT00219141)
Timeframe: Baseline to end of study (Week 36)
| Intervention | mm * ms (Mean) |
|---|---|
| Aliskiren 300 mg | -104.97 |
| Losartan 100 mg | -150.31 |
| Aliskiren/Losartan 300/100 mg | -130.65 |
(NCT00219141)
Timeframe: Baseline to end of study (Week 36)
| Intervention | mm (Mean) |
|---|---|
| Aliskiren 300 mg | -0.71 |
| Losartan 100 mg | -0.64 |
| Aliskiren/Losartan 300/100 mg | -0.86 |
(NCT00219141)
Timeframe: Baseline to end of study (Week 36)
| Intervention | mm (Mean) |
|---|---|
| Aliskiren 300 mg | -0.95 |
| Losartan 100 mg | -1.20 |
| Aliskiren/Losartan 300/100 mg | -1.17 |
(NCT00219141)
Timeframe: Baseline to end of study (Week 36)
| Intervention | percent (Mean) |
|---|---|
| Aliskiren 300 mg | 0.62 |
| Losartan 100 mg | 2.02 |
| Aliskiren/Losartan 300/100 mg | 1.92 |
(NCT00219141)
Timeframe: Baseline to end of study (Week 36)
| Intervention | g (Mean) |
|---|---|
| Aliskiren 300 mg | -9.81 |
| Losartan 100 mg | -9.92 |
| Aliskiren/Losartan 300/100 mg | -12.29 |
(NCT00219141)
Timeframe: Baseline to end of study (Week 36)
| Intervention | mL (Mean) |
|---|---|
| Aliskiren 300 mg | -7.05 |
| Losartan 100 mg | -4.52 |
| Aliskiren/Losartan 300/100 mg | -7.03 |
(NCT00219141)
Timeframe: Baseline to end of study (Week 36)
| Intervention | mL (Mean) |
|---|---|
| Aliskiren 300 mg | -3.20 |
| Losartan 100 mg | -4.73 |
| Aliskiren/Losartan 300/100 mg | -5.14 |
(NCT00219141)
Timeframe: Baseline to end of study (Week 36)
| Intervention | mm (Mean) |
|---|---|
| Aliskiren 300 mg | -0.88 |
| Losartan 100 mg | -0.89 |
| Aliskiren/Losartan 300/100 mg | -0.90 |
(NCT00219141)
Timeframe: Baseline to end of study (Week 36)
| Intervention | g/m^2 (Mean) |
|---|---|
| Aliskiren 300 mg | -4.87 |
| Losartan 100 mg | -4.79 |
| Aliskiren/Losartan 300/100 mg | -5.81 |
(NCT00219141)
Timeframe: Baseline to end of study (Week 36)
| Intervention | mL (Mean) |
|---|---|
| Aliskiren 300 mg | -3.89 |
| Losartan 100 mg | 0.24 |
| Aliskiren/Losartan 300/100 mg | -2.24 |
(NCT00219141)
Timeframe: Baseline to end of study (Week 36)
| Intervention | mm (Mean) |
|---|---|
| Aliskiren 300 mg | -1.07 |
| Losartan 100 mg | -0.97 |
| Aliskiren/Losartan 300/100 mg | -1.43 |
Two 24-hour ambulatory blood pressure monitoring (ABPM) evaluations were performed, one at baseline and one at the end of the study. For each evaluation, the ABPM device was attached to the non-dominant arm of the patient. A correlation was made between the ABPM device readings and measurements taken with a mercury sphygmomanometer and stethoscope. Following the correlation procedure, blood pressure was measured at study specified intervals. (NCT00219141)
Timeframe: Baseline the end of study (Week 36)
| Intervention | mm Hg (Least Squares Mean) | |
|---|---|---|
| Systolic | Diastolic | |
| Aliskiren 300 mg | -2.67 | -1.31 |
| Aliskiren/Losartan 300/100 mg | -6.97 | -4.11 |
| Losartan 100 mg | -3.81 | -1.92 |
18 reviews available for aldosterone and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Research Progress on the Efficacy and Safety of Spironolactone in Reversing Left Ventricular Hypertrophy in Hemodialysis Patients.
Topics: Aldosterone; Heart Failure; Humans; Hypertrophy, Left Ventricular; Multicenter Studies as Topic; Pro | 2023 |
Left ventricular remodeling and dysfunction in primary aldosteronism.
Topics: Aldosterone; Humans; Hyperaldosteronism; Hypertension; Hypertrophy, Left Ventricular; Ventricular Dy | 2021 |
Aldosterone is associated with left ventricular hypertrophy in hemodialysis patients.
Topics: Aldosterone; Body Mass Index; C-Reactive Protein; Humans; Hypertrophy, Left Ventricular; Renal Dialy | 2016 |
Aldosterone-receptor antagonism in hypertension.
Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Arrhythmias, Cardiac; D | 2009 |
Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment.
Topics: Adrenalectomy; Aldosterone; Animals; Blood Pressure; Cardiovascular System; Humans; Hyperaldosteroni | 2010 |
The role of mineralocorticoid receptor antagonists in patients with American College of Cardiology/American Heart Association stage B heart failure.
Topics: Adrenal Glands; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Enalapril; Endotheli | 2012 |
NADPH oxidases in heart failure: poachers or gamekeepers?
Topics: Aldosterone; Angiotensin II; Animals; Apoptosis; Arrhythmias, Cardiac; Enzyme Activation; Fibroblast | 2013 |
Local cardiac renin-angiotensin system: hypertension and cardiac failure.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically | 2002 |
Essential hypertension and left ventricular hypertrophy in cardiovascular disease: beyond overactivity of the renin-angiotensin-aldosterone-sodium system.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Humans; Hypertension; Hypertrophy, Left Ventricular; | 2003 |
Mineralocorticoid receptor antagonists and hypertension: is there a rationale?
Topics: Albuminuria; Aldosterone; Animals; Drug Therapy, Combination; Eplerenone; Humans; Hyperkalemia; Hype | 2004 |
Pathophysiology of heart failure following myocardial infarction.
Topics: Aldosterone; Angiotensins; Fibrosis; Heart Failure; Humans; Hypertrophy, Left Ventricular; Myocardia | 2005 |
The role of aldosterone blockers in the management of chronic heart failure.
Topics: Aldosterone; Animals; Chronic Disease; Heart Failure; Humans; Hypertrophy, Left Ventricular; Kidney; | 2005 |
"Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Drug Evaluation; Heart Failure; Humans; Hyper | 1995 |
Substrate metabolism, hormone interaction, and angiotensin-converting enzyme inhibitors in left ventricular hypertrophy.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Aldosterone; Angiotensin-Converting Enzyme Inhibitors | 1996 |
[Pathophysiology of left ventricular hypertrophy in arterial hypertension].
Topics: Aldosterone; Cyclic AMP; Growth Substances; Heart; Humans; Hypertension; Hypertrophy, Left Ventricul | 1997 |
[Hypertrophy due to left cardiac insufficiency: role of the neurohumoral system].
Topics: Aldosterone; Angiotensin II; Arginine Vasopressin; Atrial Natriuretic Factor; Heart Failure; Humans; | 1997 |
Left ventricular anatomy and function in primary aldosteronism and renovascular hypertension.
Topics: Adrenalectomy; Aldosterone; Animals; Heart; Heart Ventricles; Humans; Hyperaldosteronism; Hypertensi | 1997 |
Left ventricular hypertrophy in hypertension: etiology, treatment, and controversies.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Angiotensinogen; Animals; Hem | 1998 |
23 trials available for aldosterone and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Twenty-four-hour urinary aldosterone predicts inappropriate left ventricular mass index in patients with primary aldosteronism.
Topics: Aged; Aldosterone; Body Size; Cross-Sectional Studies; Female; Humans; Hyperaldosteronism; Hypertrop | 2013 |
Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension.
Topics: Adolescent; Adult; Aged; Aldosterone; Amiloride; Amlodipine; Angiotensin II Type 1 Receptor Blockers | 2014 |
Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Double-Blind Method; Drug Monitoring; Female; Humans; Hype | 2015 |
Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study).
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; | 2016 |
Long-term effect of efonidipine therapy on plasma aldosterone and left ventricular mass index in patients with essential hypertension.
Topics: Aged; Aldosterone; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzym | 2009 |
Aldosterone excess or escape: Treating resistant hypertension.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bloo | 2009 |
Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conve | 2010 |
Role of plasma aldosterone concentration in regression of left-ventricular mass following antihypertensive medication.
Topics: Adult; Aged; Aldosterone; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agen | 2011 |
Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension.
Topics: Aldosterone; Amides; Antihypertensive Agents; Blood Pressure; Demography; Female; Fumarates; Heart V | 2011 |
Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction.
Topics: Aged; Aged, 80 and over; Aldosterone; Analysis of Variance; Cohort Studies; Echocardiography; Female | 2012 |
Effects of olmesartan on the renin-angiotensin-aldosterone system for patients with essential hypertension after cardiac surgery--investigation using a candesartan change-over study.
Topics: Aged; Aldosterone; Analysis of Variance; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; An | 2011 |
Influence of diabetes on efficacy of aliskiren, losartan or both on left ventricular mass regression.
Topics: Aldosterone; Amides; Antihypertensive Agents; Biomarkers; Blood Pressure; Diabetes Complications; Fe | 2012 |
Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor.
Topics: Aged; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors | 2012 |
Adrenalectomy reverses myocardial fibrosis in patients with primary aldosteronism.
Topics: Adenoma; Adrenal Gland Neoplasms; Adrenalectomy; Aldosterone; Cardiomyopathies; Echocardiography; Fe | 2012 |
Hypertensive left ventricular hypertrophy: a mechanistic approach to optimizing regression assessed by cardiovascular magnetic resonance.
Topics: Adult; Aged; Aldosterone; Antihypertensive Agents; Female; Humans; Hypertension; Hypertrophy, Left V | 2012 |
Functional relevance of aldosterone for the determination of left ventricular mass.
Topics: Adult; Aldosterone; Angiotensin II; Drug Interactions; Echocardiography; Humans; Hypertrophy, Left V | 2003 |
Influence of dietary sodium on the renin-angiotensin-aldosterone system and prevalence of left ventricular hypertrophy by EKG criteria.
Topics: Aldosterone; Blood Pressure; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ve | 2005 |
Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy.
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl | 2006 |
The effects of long-term treatment on left ventricular hypertrophy in patients with essential hypertension: relation to changes in neurohumoral factors.
Topics: Adult; Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atrial | 1997 |
Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Captopril; Female; | 1998 |
Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Drug Therapy, Combination; Ec | 1999 |
Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure.
Topics: Adult; Aldosterone; Angiotensin II; Blood Pressure; Data Interpretation, Statistical; Dose-Response | 1999 |
Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
Topics: Adrenergic beta-Antagonists; Aldosterone; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2002 |
119 other studies available for aldosterone and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Comparison of Echocardiographic Changes Between Surgery and Medication Treatment in Patients With Primary Aldosteronism.
Topics: Aldosterone; Echocardiography; Humans; Hyperaldosteronism; Hypertension; Hypertrophy, Left Ventricul | 2022 |
Serum aldosterone effect on left ventricular structure and diastolic function in essential hypertension.
Topics: Aldosterone; Diastole; Echocardiography; Essential Hypertension; Female; Humans; Hypertension; Hyper | 2023 |
Diabetes mellitus is associated with more adverse non-hemodynamic left ventricular remodeling and less recovery in patients with primary aldosteronism.
Topics: Aldosterone; Diabetes Mellitus; Echocardiography; Humans; Hyperaldosteronism; Hypertension; Hypertro | 2023 |
Unique Case of Cardiomyopathy Secondary to Adrenal Adenoma (Primary-Aldosteronism).
Topics: Adenoma; Adrenocortical Adenoma; Aldosterone; Cardiomyopathies; Female; Humans; Hyperaldosteronism; | 2023 |
Autonomous Aldosterone Production and Left Ventricular Hypertrophy.
Topics: Aldosterone; Humans; Hyperaldosteronism; Hypertension; Hypertrophy, Left Ventricular | 2020 |
The relationship of plasma renin, angiotensin, and aldosterone levels to blood pressure variability and target organ damage in children with essential hypertension.
Topics: Adolescent; Age Factors; Aldosterone; Angiotensins; Biomarkers; Blood Pressure; Child; Essential Hyp | 2020 |
Hemodynamic and Non-Hemodynamic Components of Cardiac Remodeling in Primary Aldosteronism.
Topics: Adrenalectomy; Adrenocortical Adenoma; Adult; Aldosterone; Blood Pressure; Echocardiography; Essenti | 2021 |
Aldosterone induces left ventricular subclinical systolic dysfunction: a strain imaging study.
Topics: Adult; Aged; Aldosterone; Echocardiography; Essential Hypertension; Female; Heart; Humans; Hyperaldo | 2018 |
KCNJ5 mutation as a predictor for resolution of hypertension after surgical treatment of aldosterone-producing adenoma.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Adenoma; Adult; Aldosterone; Female; G Prote | 2018 |
Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population.
Topics: Aged; Aldosterone; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Glucose; Cholesterol, L | 2018 |
Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population.
Topics: Aged; Aldosterone; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Glucose; Cholesterol, L | 2018 |
Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population.
Topics: Aged; Aldosterone; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Glucose; Cholesterol, L | 2018 |
Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population.
Topics: Aged; Aldosterone; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Glucose; Cholesterol, L | 2018 |
Cortisol Excess in Patients With Primary Aldosteronism Impacts Left Ventricular Hypertrophy.
Topics: Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Adenoma; Adult; Aldosterone; | 2018 |
Changes in serum and intracardiac fibroblast growth factor 23 during the progression of left ventricular hypertrophy in hypertensive model rats.
Topics: Aldosterone; Animals; Bone and Bones; Chronic Kidney Disease-Mineral and Bone Disorder; Disease Mode | 2019 |
Evaluation of docosahexaenoic acid in a dog model of hypertension induced left ventricular hypertrophy.
Topics: Aldosterone; Animals; Arachidonic Acid; Blood Pressure; Disease Models, Animal; Docosahexaenoic Acid | 2013 |
Telmisartan delays myocardial fibrosis in rats with hypertensive left ventricular hypertrophy by TGF-β1/Smad signal pathway.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzo | 2014 |
[Correlation between plasma aldosterone concentration and left ventricular structure in hypertensive patients].
Topics: Adolescent; Adult; Aged; Aldosterone; Female; Heart Ventricles; Humans; Hypertension; Hypertrophy, L | 2013 |
Adiponectin as an independent predictor of left ventricular hypertrophy in nondiabetic patients with hypertension.
Topics: Adiponectin; Aged; Aldosterone; Biomarkers; Female; Hemodynamics; Humans; Hypertension; Hypertrophy, | 2015 |
Primary aldosteronism and essential hypertension: assessment of cardiovascular risk at diagnosis and after treatment.
Topics: Adult; Aged; Aldosterone; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Essential Hyperten | 2014 |
Adiponectin and Aldosterone in Left Ventricular Hypertrophy: An Intriguing Interplay.
Topics: Adiponectin; Aldosterone; Humans; Hypertension; Hypertrophy, Left Ventricular | 2018 |
KCNJ5 gene somatic mutations affect cardiac remodelling but do not preclude cure of high blood pressure and regression of left ventricular hypertrophy in primary aldosteronism.
Topics: Adenoma; Adrenal Cortex Neoplasms; Adrenalectomy; Aldosterone; Female; Follow-Up Studies; G Protein- | 2014 |
Plasma aldosterone and its relationship with left ventricular mass in hypertensive patients with early-stage chronic kidney disease.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Creatinine; Female; Humans; Hypertension; Hypertrophy, Lef | 2015 |
Aldosterone and abnormal left ventricular geometry in chronic kidney disease.
Topics: Aldosterone; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Renal Insufficiency, | 2015 |
Plasma aldosterone and left ventricular diastolic function in treatment-naïve patients with hypertension: tissue-Doppler imaging study.
Topics: Adult; Aldosterone; Analysis of Variance; Case-Control Studies; Chi-Square Distribution; Diastole; E | 2015 |
Association of Mineralocorticoid Receptor Polymorphism I180V With Left Ventricular Hypertrophy in Resistant Hypertension.
Topics: Adult; Aldosterone; Cross-Sectional Studies; Female; Humans; Hypertension; Hypertrophy, Left Ventric | 2016 |
Association of Post-Saline Load Plasma Aldosterone Levels With Left Ventricular Hypertrophy in Primary Hypertension.
Topics: Adult; Aldosterone; Echocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; I | 2016 |
Heart Failure With Preserved Ejection Fraction Induces Beiging in Adipose Tissue.
Topics: Adipocytes, Brown; Adipocytes, White; Adipose Tissue, Brown; Adipose Tissue, White; Aldosterone; Ani | 2016 |
Cardiac Remodeling in Patients With Primary and Secondary Aldosteronism: A Tissue Doppler Study.
Topics: Adult; Aged; Aldosterone; Biomarkers; Biomechanical Phenomena; Blood Pressure; Case-Control Studies; | 2016 |
Prevalence, Neurohormonal Correlates, and Prognosis of Heart Failure Stages in the Community.
Topics: Adult; Aged; Aldosterone; C-Reactive Protein; Coronary Artery Disease; Diabetes Mellitus; Female; He | 2016 |
Plasma aldosterone and its relationships with left ventricular mass in essential hypertensive patients with the metabolic syndrome.
Topics: Adult; Aldosterone; Blood Pressure; Echocardiography; Female; Humans; Hypertension; Hypertrophy, Lef | 2008 |
Cardiac benefits of mineralocorticoid receptor inhibition in renal failure.
Topics: Aldosterone; Animals; Cohort Studies; Disease Models, Animal; Humans; Hypertrophy, Left Ventricular; | 2008 |
Effects of aldosterone on the heart: beyond systemic hemodynamics?
Topics: Aldosterone; Animals; Blood Pressure; Heart; Humans; Hypertension; Hypertrophy, Left Ventricular | 2008 |
Inappropriate left ventricular mass in patients with primary aldosteronism.
Topics: Adaptation, Physiological; Adult; Aged; Aldosterone; Echocardiography; Female; Humans; Hyperaldoster | 2008 |
A nonpeptide, piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes.
Topics: Administration, Oral; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin | 2008 |
Effect of spironolactone on hypertrophy of left ventricular myocardium in wistar rats with experimental uremia.
Topics: Aldosterone; Animals; Creatinine; Electrolytes; Hypertrophy, Left Ventricular; Kidney Failure, Chron | 2008 |
Left ventricular hypertrophy and geometry in hypertensive patients with chronic kidney disease.
Topics: Aged; Aldosterone; Blood Pressure Determination; Case-Control Studies; Catecholamines; Chronic Disea | 2009 |
Sodium chloride and aldosterone: harbingers of hypertension-related cardiovascular disease.
Topics: Aldosterone; Animals; Blood Pressure; Cardiovascular Diseases; Echocardiography; Humans; Hypertensio | 2009 |
Independent relations of left ventricular structure with the 24-hour urinary excretion of sodium and aldosterone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aldosterone; Blood Pressure; Echocardiography; Female; H | 2009 |
Atrial fibrillation in primary aldosteronism.
Topics: Adult; Aldosterone; Atrial Fibrillation; Female; Humans; Hyperaldosteronism; Hypertension; Hypertrop | 2009 |
[Inhibitory effect on activated renin-angiotensin system by astragaloside IV in rats with pressure-overload induced cardiac hypertrophy].
Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomegaly; Enzyme-Linked Immunosorbent Assa | 2009 |
Effects of polydatin on attenuating ventricular remodeling in isoproterenol-induced mouse and pressure-overload rat models.
Topics: Aldosterone; Angiotensin II; Animals; Aorta, Abdominal; Blood Pressure; Cardiovascular Agents; Colla | 2010 |
Association of HSD3B1 and HSD3B2 gene polymorphisms with essential hypertension, aldosterone level, and left ventricular structure.
Topics: Adult; Aldosterone; Case-Control Studies; Echocardiography; Female; Genotype; Haplotypes; Humans; Hy | 2010 |
Dietary sodium, aldosterone, and left ventricular mass changes during long-term inhibition of the renin-angiotensin system.
Topics: Adult; Aged; Aldosterone; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihypert | 2010 |
[Effect of Chrysanthemum indicum on ventricular remodeling in rats].
Topics: Aldosterone; Angiotensin II; Animals; Chrysanthemum; Disease Models, Animal; Drugs, Chinese Herbal; | 2010 |
[Effects of Bai-Chuan capsule on left ventricular hypertrophy and correlative indexes].
Topics: Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Apiaceae; Blood Pressure; Capsules; C | 2010 |
The association of serum potassium level with left ventricular mass in patients with primary aldosteronism.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Case-Control Studies; Diastole; Female; Heart Ventricles; | 2011 |
Cardiovascular changes in patients with primary aldosteronism after surgical or medical treatment.
Topics: Adenoma; Adrenal Cortex Neoplasms; Adrenal Hyperplasia, Congenital; Adult; Aged; Aldosterone; Blood | 2012 |
A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone.
Topics: Aldosterone; Animals; Blood Pressure; Blotting, Western; Collagen; Cytokines; Disease Models, Animal | 2011 |
Subdose of fasudil suppresses myocardial fibrosis in aldosterone-salt-treated uninephrectomized rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aldosterone; Animals; Antihypertensive Agents; Biomar | 2011 |
Association of left ventricular mass with the AGTR1 A1166C polymorphism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aldosterone; Echocardiography; Female; Heart Ventricles; | 2012 |
Predictive factors of left ventricular mass changes after treatment of primary aldosteronism.
Topics: Adrenalectomy; Adult; Aldosterone; Blood Pressure; Female; Heart Ventricles; Humans; Hyperaldosteron | 2012 |
Urinary corticosteroid excretion predicts left ventricular mass and proteinuria in chronic kidney disease.
Topics: Aged; Aldosterone; Biomarkers; Cross-Sectional Studies; Desoxycorticosterone; Female; Gas Chromatogr | 2012 |
[Peculiarities of cardiac contractile function in patients with arterial hypertension depending on temperament and anxiety state].
Topics: Adult; Aldosterone; Anxiety; Comorbidity; Diastole; Echocardiography; Humans; Hypertension; Hypertro | 2011 |
Early apoptosis in different models of cardiac hypertrophy induced by high renin-angiotensin system activity involves CaMKII.
Topics: Aldosterone; Animals; Apoptosis; Blood Pressure; Calcium; Calcium-Calmodulin-Dependent Protein Kinas | 2012 |
Interferon-γ ablation exacerbates myocardial hypertrophy in diastolic heart failure.
Topics: Aldosterone; Animals; Autophagy; Disease Models, Animal; Disease Progression; Fibrosis; Heart Failur | 2012 |
Transient prehypertensive treatment in spontaneously hypertensive rats: a comparison of losartan and amlodipine regarding long-term blood pressure, cardiac and renal protection.
Topics: Aldosterone; Amlodipine; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Cardioton | 2012 |
Aldosterone contributes to elevated left ventricular mass in black boys.
Topics: Adolescent; Age Factors; Aldosterone; Analysis of Variance; Angiotensin II; Biomarkers; Black or Afr | 2013 |
Enhanced resistance to permeability transition in interfibrillar cardiac mitochondria in dogs: effects of aging and long-term aldosterone infusion.
Topics: Aging; Aldosterone; Animals; Cell Membrane Permeability; Dogs; Female; Hypertension; Hypertrophy, Le | 2013 |
Association of aldosterone with left ventricular mass in hypertension: interaction with plasma fibrinogen levels.
Topics: Adult; Aged; Aldosterone; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Heart Ventricl | 2013 |
Structural changes in small resistance arteries and left ventricular geometry in patients with primary and secondary hypertension.
Topics: Adult; Aged; Aldosterone; Arteries; Echocardiography; Female; Heart Ventricles; Humans; Hypertension | 2002 |
TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension.
Topics: Aldosterone; Blood Pressure; Cohort Studies; Collagen; Collagen Type I; Echocardiography; Electrocar | 2002 |
Soluble cell adhesion molecules in hypertensive concentric left ventricular hypertrophy.
Topics: Adult; Aged; Aldosterone; Carotid Arteries; Case-Control Studies; Cell Adhesion Molecules; E-Selecti | 2002 |
Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension.
Topics: Aged; Aldosterone; Angiotensin II; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood Vess | 2002 |
Brain natriuretic peptide as a risk marker for incident hypertensive cardiovascular events.
Topics: Aged; Aging; Aldosterone; Atrial Natriuretic Factor; Biomarkers; Blood Pressure; Catecholamines; Dis | 2002 |
Effect of Salvia miltiorrhiza on left ventricular hypertrophy and cardiac aldosterone in spontaneously hypertensive rats.
Topics: Aldosterone; Animals; Drugs, Chinese Herbal; Hypertension; Hypertrophy, Left Ventricular; Male; Myoc | 2002 |
Upregulation of ligand, receptor system, and amidating activity of adrenomedullin in left ventricular hypertrophy of severely hypertensive rats: effects of angiotensin-converting enzyme inhibitors and diuretic.
Topics: Adrenomedullin; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic F | 2003 |
The role of biochemical tests and clinical symptoms in differential diagnosis of primary aldosteronism.
Topics: Adult; Age Factors; Aged; Aldosterone; Biomarkers; Blood Pressure; Blood Pressure Determination; Dia | 2003 |
Relationship between hypertensive left ventricular hypertrophy, neurohormonal factors and ventricular arrhythmias in very old patients.
Topics: Aged; Aged, 80 and over; Aldosterone; Angiotensin II; Arrhythmias, Cardiac; Biomarkers; Coronary Ang | 2004 |
Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy.
Topics: Aldosterone; Angiotensin II; Animals; Apoptosis; Blood Pressure; Cardiomegaly; Cell Size; Eplerenone | 2004 |
Association of -344/T/C aldosterone synthase polymorphism (CYP11B2) with left ventricular structure and humoral parameters in young normotensive men.
Topics: Adolescent; Adult; Aldosterone; Alleles; Base Sequence; Blood Pressure; Cross-Sectional Studies; Cyt | 2004 |
Serum aldosterone and the incidence of hypertension in nonhypertensive persons.
Topics: Aldosterone; Blood Pressure; Female; Heart Ventricles; Humans; Hyperaldosteronism; Hypertension; Hyp | 2004 |
The influence of aldosterone on the development of left ventricular geometry and hypertrophy in patients with essential hypertension.
Topics: Aged; Aldosterone; Body Mass Index; Echocardiography; Female; Heart Ventricles; Humans; Hypertension | 2004 |
11beta-Hydroxysteroid dehydrogenase type 2 activity is associated with left ventricular mass in essential hypertension.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Aldosterone; Blood Pressure; Cohort Studies; Cortodoxon | 2005 |
Progressive left ventricular hypertrophy after withdrawal of long-term ACE inhibition following experimental myocardial infarction.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Endothelium, Vascular; Hypertrophy, | 2006 |
Cardiac consequences of aldosterone excess in human hypertension.
Topics: Adrenergic beta-Antagonists; Aldosterone; Angiotensin II; Blood Pressure; Calcium Channel Blockers; | 2006 |
Role of aldosterone in left ventricular hypertrophy in hypertension.
Topics: Adrenergic beta-Antagonists; Adrenocortical Adenoma; Adult; Aldosterone; Angiotensin II; Blood Press | 2006 |
Aldosterone and left ventricular hypertrophy in Afro-Caribbean subjects with low renin hypertension.
Topics: Adult; Aged; Aldosterone; Black People; Blood Pressure; Caribbean Region; Echocardiography; Female; | 2006 |
Too much aldosterone--more common than we ever realized?
Topics: Adult; Aged; Aldosterone; Black People; Blood Pressure; Caribbean Region; Female; Humans; Hypertensi | 2006 |
Role of aldosterone in left ventricular hypertrophy among African-American patients with end-stage renal disease on hemodialysis.
Topics: Aged; Aldosterone; Black or African American; Diabetes Mellitus; Humans; Hypertension; Hypertrophy, | 2007 |
Association of low-grade urinary albumin excretion with left ventricular hypertrophy in the general population: a reply.
Topics: Albuminuria; Aldosterone; Blood Pressure; Humans; Hypertrophy, Left Ventricular; Sodium Chloride | 2007 |
Left ventricular hypertrophy and geometry in untreated essential hypertension is associated with blood levels of aldosterone and procollagen type III amino-terminal peptide.
Topics: Aldosterone; Echocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Linear M | 2007 |
Arterial plasma vasopressin and aldosterone predict left ventricular mass in men who develop hypertension over 20 years.
Topics: Adult; Aldosterone; Analysis of Variance; Antihypertensive Agents; Arteries; Biomarkers; Blood Press | 2007 |
Effects of fenofibrate on cardiac remodeling in aldosterone-induced hypertension.
Topics: Aldosterone; Animals; Blood Pressure; Extracellular Matrix; Fenofibrate; Fibrosis; Heart; Heart Rate | 2007 |
Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism.
Topics: Adenoma; Adrenal Gland Neoplasms; Adrenalectomy; Aldosterone; Antihypertensive Agents; Female; Follo | 2007 |
[Influnce of Tinglizi on some neuroendocrine factors and type I and III collagen in ventricular remodeling induced by abdominal aortic banding in rats].
Topics: Aldosterone; Angiotensin II; Animals; Aorta, Abdominal; Blood Pressure; Collagen; Constriction; Drug | 2007 |
Diastolic dysfunction is associated with insulin resistance, but not with aldosterone level in normotensive offspring of hypertensive families.
Topics: Adult; Aldosterone; Case-Control Studies; Female; Genetic Predisposition to Disease; Heart Failure, | 2008 |
Biological determinants of aldosterone-induced cardiac fibrosis in rats.
Topics: Aldosterone; Animals; Blotting, Northern; Collagen; Fibrosis; Heart; Histocytochemistry; Hypertensio | 1995 |
Left ventricular mass in hereditary human hypertension: glucocorticoid-suppressible hyperaldosteronism.
Topics: Adolescent; Adult; Aldosterone; Blood Pressure; Child; Female; Genotype; Glucocorticoids; Humans; Hy | 1995 |
[Evaluation of the efficacy and safety of monotherapy for significant essential hypertension in adolescents with use of enalapril].
Topics: Adolescent; Aldosterone; Child; Echocardiography; Enalapril; Evaluation Studies as Topic; Female; Ga | 1995 |
Clinical evidence for an association between left ventricular geometric adaptation and extracardiac target organ damage in essential hypertension.
Topics: Aldosterone; Catecholamines; Cholesterol; Creatinine; Female; Humans; Hypertension; Hypertrophy, Lef | 1995 |
[Restructuring of the collagen network in hypertension: role of the angiotensin-aldosterone system].
Topics: Aldosterone; Animals; Collagen; Fibrosis; Humans; Hypertension; Hypertrophy, Left Ventricular; Renin | 1993 |
Mineralocorticoids, hypertension, and cardiac fibrosis.
Topics: Aldosterone; Animals; Blood Pressure; Collagen; Desoxycorticosterone; Endomyocardial Fibrosis; Hydro | 1994 |
Left ventricular hypertrophy in asymptomatic essential hypertension: its relationship with aldosterone and the increase in sodium-proton exchanger activity.
Topics: Adult; Age Factors; Aldosterone; Blood Pressure; Case-Control Studies; Erythrocytes; Female; Humans; | 1993 |
Left ventricular mass and geometry before and after etiologic treatment in renovascular hypertension, aldosterone-producing adenoma, and pheochromocytoma.
Topics: Adenoma; Adrenal Gland Neoplasms; Adult; Aldosterone; Blood Pressure; Echocardiography; Female; Hear | 1993 |
Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension.
Topics: Adult; Aldosterone; Analysis of Variance; Blood Pressure; Female; Humans; Hypertension; Hypertrophy, | 1993 |
Aldosterone levels and cardiac hypertrophy in professional cyclists.
Topics: Adult; Aldosterone; Bicycling; Echocardiography; Humans; Hypertrophy, Left Ventricular; Male | 1995 |
Influence of humoral and neurohormonal factors on cardiovascular hypertrophy in untreated essential hypertensives.
Topics: Adult; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Blood Pressure; Blood Pressure Monito | 1996 |
Influence of aortic impedance on the development of pressure-overload left ventricular hypertrophy in rats.
Topics: Aldosterone; Angiotensin II; Animals; Aorta, Abdominal; Aorta, Thoracic; Aortic Coarctation; Blood P | 1996 |
Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass.
Topics: Age Factors; Aged; Aldosterone; Blood Pressure; Body Mass Index; Echocardiography; Female; Humans; H | 1997 |
Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism.
Topics: Adult; Aged; Aldosterone; Electrocardiography; Female; Humans; Hyperaldosteronism; Hypertension; Hyp | 1997 |
Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension.
Topics: Adrenal Gland Neoplasms; Adult; Aldosterone; Cushing Syndrome; Echocardiography; Female; Humans; Hyp | 1997 |
Influence of different dietary salts on the cardiovascular and renal effects of moxonidine in spontaneously hypertensive rats.
Topics: Aldosterone; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Drinking; | 1997 |
Relationship between some humoral factors and left ventricular hypertrophy in essential hypertension.
Topics: Aldosterone; Angiotensin II; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Midd | 1996 |
[Cardio-protection and cardio-reparation in systemic arterial hypertension].
Topics: Aldosterone; Antihypertensive Agents; Electrocardiography; Humans; Hypertension; Hypertrophy, Left V | 1997 |
Neurohormonal activity and left ventricular geometry in patients with essential arterial hypertension.
Topics: Aldosterone; Atrial Natriuretic Factor; Case-Control Studies; Echocardiography, Doppler; Female; Hea | 1998 |
Inadequate suppression of angiotensin II modulates left ventricular structure in humans.
Topics: Adult; Aldosterone; Angiotensin II; Blood Pressure; Humans; Hypertrophy, Left Ventricular; Male; Ren | 1998 |
Modifications of myocardial Na+,K(+)-ATPase isoforms and Na+/Ca2+ exchanger in aldosterone/salt-induced hypertension in guinea pigs.
Topics: Aldosterone; Animals; Blotting, Northern; Blotting, Western; Echocardiography; Guinea Pigs; Hyperten | 1998 |
In vivo left ventricular function and collagen expression in aldosterone/salt-induced hypertension.
Topics: Aldosterone; Animals; Collagen; Electrolytes; Fibrosis; Guinea Pigs; Hormones; Hypertension; Hypertr | 1998 |
Left ventricular systolic function in primary aldosteronism and hypertension.
Topics: Adult; Aldosterone; Echocardiography, Doppler; Female; Humans; Hyperaldosteronism; Hypertension; Hyp | 1998 |
Clinic-daytime blood pressure difference and cardiovascular damage.
Topics: Adult; Aldosterone; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Carotid Arteries; Cholest | 1999 |
Lack of association between a polymorphism of the aldosterone synthase gene and left ventricular structure.
Topics: Adult; Aged; Aldosterone; Cytochrome P-450 CYP11B2; Echocardiography; Female; Genotype; Humans; Hype | 1999 |
Ventricular adrenomedullin levels correlate with the extent of cardiac hypertrophy in rats.
Topics: Adrenomedullin; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Age | 1999 |
Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis.
Topics: Adrenergic alpha-Antagonists; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Blo | 1999 |
[Left ventricular myocardial structure and function in patients with primary aldosteronism].
Topics: Adrenalectomy; Adult; Aldosterone; Blood Flow Velocity; Blood Pressure; Echocardiography, Doppler; F | 1999 |
Differential responses of circulating and tissue adrenomedullin and gene expression to volume overload.
Topics: Adrenomedullin; Aldosterone; Animals; Aorta, Thoracic; Arteriovenous Shunt, Surgical; Atrial Natriur | 2000 |
Non-corresponding effects of an angiotensin-converting enzyme inhibitor on cardiac and vascular hypertrophy in spontaneously hypertensive rats.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine Vasopressin; Blood Pressure | 2000 |
Arterial pressure, left ventricular mass, and aldosterone in essential hypertension.
Topics: Adult; Aldosterone; Black People; Blood Pressure; Body Mass Index; Canada; Circadian Rhythm; Electro | 2001 |
Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunction.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Blood Pressure; Carboxylic Acids; Endothelin Recept | 2001 |
[Study on the relation between hypertensive left ventricular hypertrophy in very old people with neurohormonal factors and ventricular arrhythmias].
Topics: Aged; Aged, 80 and over; Aldosterone; Angiotensin II; Arrhythmias, Cardiac; Female; Humans; Hyperten | 2000 |
Effects of hormone replacement therapy on left ventricular hypertrophy and growth-promoting factors in hypertensive postmenopausal women.
Topics: Aldosterone; Echocardiography; Estrogen Replacement Therapy; Female; Growth Substances; Humans; Hype | 2002 |
[The interrelationship between humoral factors and the indices of left ventricular myocardial hypertrophy in hypertension].
Topics: Adrenocorticotropic Hormone; Adult; Aldosterone; Female; Hemodynamics; Humans; Hydrocortisone; Hyper | 1992 |